Individualized progenitor cells
Patent Information
- Application Number
- CN202480084046.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-11-15
- Filing Date
- 2024-11-14
- Publication Date
- 2026-08-04
AI Technical Summary
同种异体干细胞的施用已显现出一些治疗信号,然而,这种治疗方式受限于此类细胞体内存活时间较短的固有缺陷
Smart Images

Figure CN122514591A_ABST
Abstract
Description
[0001] Cross-reference to related applications This application claims the benefit of U.S. Provisional Patent Application No. 63 / 599,440, filed November 15, 2023, entitled “Individualized Progenitor Cells,” the entire contents of which are incorporated herein by reference. Technical Field
[0002] This invention relates to the field of regenerative medicine, and more specifically, to the generation of progenitor cells from pluripotent stem cells, and even more specifically, to the generation, expansion, and use of tissue-specific progenitor cells from pluripotent stem cells. Background Technology
[0003] Stem cell therapy has revolutionized medical practice, offering, for the first time, the possibility of curing previously incurable diseases by forming new tissues. The application of allogeneic stem cells has shown some therapeutic signals; however, this approach is limited by the inherent limitation of the short lifespan of these cells in vivo. In fact, research has shown that the therapeutic effects of allogeneic stem cells do not originate from the cells themselves, but are mediated by apoptotic bodies. This invention provides a method for therapeutic use using autologous cells, achieved by generating dedifferentiated pluripotent stem cells and forming tissue-specific progenitor cells that can be stored or used for treatment when needed. Summary of the Invention
[0004] The following is an overview of the numbering aspects of the present invention.
[0005] 1. A method for generating tissue-specific progenitor cells from pluripotent stem cells, comprising exposing the pluripotent stem cells to factors generated by representative tissue cells.
[0006] 2. The method of aspect 1, wherein the pluripotent stem cells are capable of forming teratomas in immunodeficient mice.
[0007] 3. The method of aspect 1, wherein the pluripotent stem cells are generated through parthenogenesis.
[0008] 4. The method of aspect 3, wherein the parthenogenesis is carried out by inducing calcium flow in one or more oocytes.
[0009] 5. The method of aspect 4, wherein the calcium flow is induced by application of a calcium ion carrier.
[0010] 6. The method of aspect 5, wherein the calcium ion carrier is A23187.
[0011] 7. The method of aspect 1, wherein the pluripotent stem cells are generated by somatic cell nuclear transfer.
[0012] 8. The method of aspect 1, wherein the pluripotent stem cells are generated by inducing pluripotency.
[0013] 9. The method of aspect 8, wherein the induced pluripotency is obtained by transfecting cells with a dedifferentiation factor.
[0014] 10. The method of aspect 9, wherein the dedifferentiation factor is a pluripotency-related gene.
[0015] 11. The method of aspect 10, wherein the pluripotency-associated gene is OCT4.
[0016] 12. The method of aspect 10, wherein the pluripotency-associated gene is NANOG.
[0017] 13. The method of aspect 10, wherein the pluripotency-associated gene is KLF.
[0018] 14. The method of aspect 10, wherein the pluripotency-associated gene is HER2.
[0019] 15. The method of aspect 10, wherein the pluripotency-associated gene is SOX-2.
[0020] 16. The method of aspect 10, wherein the pluripotency-associated gene is PIM1.
[0021] 17. The method of aspect 10, wherein the pluripotency-associated gene is hTERT.
[0022] 18. The method of aspect 8, wherein the pluripotency is induced by applying a pluripotency factor together with one or more dedifferentiation factors.
[0023] 19. The method of aspect 18, wherein the dedifferentiation factor is a conditioned medium derived from embryonic stem cells.
[0024] 20. The method of aspect 18, wherein the dedifferentiation factor is a conditioned medium derived from pluripotent stem cells.
[0025] 21. The method of aspect 18, wherein the dedifferentiation factor is a conditioned medium derived from pluripotent stem cells exposed to cellular stress.
[0026] 22. The method of aspect 21, wherein the cellular stress is selected from the group of stressors: a) hypoxia; b) metabolic stress; c) high temperature; d) low temperature; e) hypotonic stress; f) hypertonic stress; and e) proteasome blockade stress.
[0027] 23. The method of aspect 18, wherein the dedifferentiation factor is a conditioned medium derived from mesenchymal stem cells.
[0028] 24. The method of aspect 23, wherein the mesenchymal stem cells express CD73.
[0029] 25. The method of aspect 23, wherein the mesenchymal stem cells express CD105.
[0030] 26. The method of aspect 23, wherein the mesenchymal stem cells express c-met.
[0031] 27. The method of aspect 23, wherein the mesenchymal stem cells express leukemia inhibitory factors.
[0032] 28. The method of aspect 23, wherein the mesenchymal stem cells express the IL-10 receptor.
[0033] 29. The method of aspect 23, wherein the mesenchymal stem cells express STAT3.
[0034] 30. The method of aspect 23, wherein the mesenchymal stem cells express FoxP3.
[0035] 31. The method of aspect 23, wherein the mesenchymal stem cells express AIRE.
[0036] 32. The method of aspect 23, wherein the mesenchymal stem cells express indoleamine 2,3-dioxygenase.
[0037] 33. The method of aspect 23, wherein the mesenchymal stem cells express CD132.
[0038] 34. The method of aspect 23, wherein the mesenchymal stem cells express c-kit.
[0039] 35. The method of aspect 23, wherein the mesenchymal stem cells express PD-L1.
[0040] 36. The method of aspect 23, wherein the mesenchymal stem cells express TGF-β.
[0041] 37. The method of aspect 23, wherein the mesenchymal stem cells express endothelial annexin.
[0042] 38. The method of aspect 23, wherein the mesenchymal stem cells express arginase.
[0043] 39. The method of aspect 23, wherein the mesenchymal stem cells express galactolectin-1.
[0044] 40. The method of aspect 23, wherein the mesenchymal stem cells express galactolectin-3.
[0045] 41. The method of aspect 23, wherein the mesenchymal stem cells express galactolectin-7.
[0046] 42. The method of aspect 23, wherein the mesenchymal stem cells express TIMP-1.
[0047] 43. The method of aspect 23, wherein the mesenchymal stem cells express TIMP-3.
[0048] 44. The method of aspect 23, wherein the mesenchymal stem cells express urokinase plasminogen activator.
[0049] 45. The method of aspect 23, wherein the mesenchymal stem cells express protein C.
[0050] 46. The method of aspect 23, wherein the mesenchymal stem cells express antithrombin III.
[0051] 47. The method of aspect 23, wherein the mesenchymal stem cells express soluble HLA-G.
[0052] 48. The method of aspect 23, wherein the mesenchymal stem cells express plasminogen.
[0053] 49. The method of aspect 23, wherein the mesenchymal stem cells express the IL-7 receptor.
[0054] 50. The method of aspect 23, wherein the mesenchymal stem cells express interleukin-12 p40 homodimer.
[0055] 51. The method of aspect 23, wherein the mesenchymal stem cells do not express HLA-II.
[0056] 52. The method of aspect 23, wherein the mesenchymal stem cells do not express HLA-DR.
[0057] 53. The method of aspect 23, wherein the mesenchymal stem cells do not express CD14.
[0058] 54. The method of aspect 23, wherein the mesenchymal stem cells do not express CD16.
[0059] 55. The method of aspect 23, wherein the mesenchymal stem cells do not express CD34.
[0060] 56. The method of aspect 23, wherein the mesenchymal stem cells are isolated by expression of CD73 and subsequently expanded.
[0061] 57. The method of aspect 23, wherein the mesenchymal stem cells are isolated by c-met expression and subsequently expanded.
[0062] 58. The method of aspect 23, wherein the mesenchymal stem cells are isolated by expression of c-kit and subsequently expanded.
[0063] 59. The method of aspect 23, wherein the mesenchymal stem cells are isolated by expression of DAF and subsequently expanded.
[0064] 60. The method of aspect 23, wherein the mesenchymal stem cells are isolated by expression of interleukin-10 receptors and subsequently expanded.
[0065] 61. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from omentum tissue.
[0066] 62. The method of aspect 61, wherein the omental tissue is degraded using collagenase and / or trypsin prior to separating the cells.
[0067] 63. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from bone marrow.
[0068] 64. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from cadaveric bone marrow.
[0069] 65. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from the skin tissue.
[0070] 66. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from adipose tissue.
[0071] 67. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from placental tissue.
[0072] 68. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from chorionic placental tissue.
[0073] 69. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from umbilical cord tissue.
[0074] 70. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from the subepithelial tissue of the umbilical cord.
[0075] 71. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from peripheral blood.
[0076] 72. The method of aspect 71, wherein the peripheral blood is obtained after mobilization.
[0077] 73. The method of aspect 72, wherein the mobilization is induced by treatment with an SCF-1 / CXCR4 interaction inhibitor.
[0078] 74. The method of aspect 73, wherein the mobilizing agent is a small molecule inhibitor of CXCR4.
[0079] 75. The method of aspect 74, wherein the small molecule inhibitor of CXCR4 is Mozibil.
[0080] 76. The method of aspect 72, wherein the mobilizing agent is a small interfering RNA that targets CXCR4.
[0081] 77. The method of aspect 72, wherein the mobilizing agent is a small interfering RNA targeting SDF-1.
[0082] 78. The method of aspect 72, wherein the mobilizing agent is a small hairpin RNA that targets CXCR4.
[0083] 79. The method of aspect 72, wherein the mobilizing agent is a small hairpin RNA targeting SDF-1.
[0084] 80. The method of aspect 72, wherein the mobilizing agent is a small interfering RNA that targets CXCR4.
[0085] 81. The method of aspect 72, wherein the mobilizing agent is a small interfering RNA targeting SDF-1.
[0086] 82. The method of aspect 72, wherein the mobilizing agent is a ribozyme targeting CXCR4.
[0087] 83. The method of aspect 72, wherein the mobilizing agent is a ribozyme targeting SDF-1.
[0088] 84. The method of aspect 72, wherein the mobilizing agent is a hammerhead ribozyme targeting CXCR4.
[0089] 85. The method of aspect 72, wherein the mobilizing agent is a hammerhead ribozyme targeting SDF-1.
[0090] 86. The method of aspect 72, wherein the mobilizing agent is an antisense oligonucleotide molecule targeting CXCR4.
[0091] 87. The method of aspect 72, wherein the mobilizing agent is an antisense oligonucleotide molecule targeting SDF-1.
[0092] 88. The method of aspect 72, wherein the mobilizing agent is cyclosporine.
[0093] 89. The method of aspect 72, wherein the mobilizing agent is cyclophosphamide.
[0094] 90. The method of aspect 72, wherein the mobilizing agent is VEGF.
[0095] 91. The method of aspect 72, wherein the mobilizing agent is a flt-3 ligand.
[0096] 92. The method of aspect 72, wherein the mobilizing agent is interleukin-11.
[0097] 93. The method of aspect 72, wherein the mobilizing agent is TNF-α.
[0098] 94. The method of aspect 72, wherein the mobilizing agent is G-CSF.
[0099] 95. The method of aspect 72, wherein the mobilizing agent is M-CSF.
[0100] 96. The method of aspect 72, wherein the mobilizing agent is GM-CSF.
[0101] 97. The method of aspect 72, wherein the mobilizing agent is IL-3.
[0102] 98. The method of aspect 72, wherein the mobilizing agent is thrombopoietin.
[0103] 99. The method of aspect 72, wherein the mobilizing agent is hepatocyte growth factor.
[0104] 100. The method of aspect 72, wherein the mobilizing agent is FGF-1.
[0105] 101. The method of aspect 72, wherein the mobilizing agent is FGF-2.
[0106] 102. The method of aspect 72, wherein the mobilizing agent is cyclophosphamide.
[0107] 103. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from hair follicles.
[0108] 104. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from the dental pulp.
[0109] 105. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from endometrial tissue.
[0110] 106. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from the fallopian tube.
[0111] 107. The method of aspects 56 to 60, wherein the mesenchymal stem cells are separated from menstrual blood.
[0112] 108. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from umbilical cord blood.
[0113] 109. The method of aspects 56 to 60, wherein the mesenchymal stem cells are isolated from amniotic tissue.
[0114] 110. The method of aspects 56 to 60, wherein the mesenchymal stem cells are separated from amniotic fluid.
[0115] 111. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interferon-γ.
[0116] 112. The method of aspect 111, wherein the interferon-γ is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 25% from baseline.
[0117] 113. The method of aspect 111, wherein the interferon-γ is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 50% from baseline.
[0118] 114. The method of aspect 111, wherein the interferon-γ is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 100% from baseline.
[0119] 115. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to TNF-α.
[0120] 116. The method of aspect 115, wherein the TNF-α is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 25% from baseline.
[0121] 117. The method of aspect 115, wherein the TNF-α is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 50% from baseline.
[0122] 118. The method of aspect 115, wherein the TNF-α is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 100% from baseline.
[0123] 119. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to TRAIL.
[0124] 120. The method of aspect 119, wherein the TRAIL is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 25% from baseline.
[0125] 121. The method of aspect 119, wherein the TRAIL is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 50% from baseline.
[0126] 122. The method of aspect 119, wherein the TRAIL is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 100% from baseline.
[0127] 123. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to lymphotoxin.
[0128] 124. The method of aspect 123, wherein the lymphotoxin is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of interleukin-10 receptors by 25% from baseline.
[0129] 125. The method of aspect 123, wherein the lymphotoxin is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of interleukin-10 receptors by 50% from baseline.
[0130] 126. The method of aspect 123, wherein the lymphotoxin is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of interleukin-10 receptors by 100% from baseline.
[0131] 127. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to TRANCE.
[0132] 128. The method of aspect 127, wherein the TRANCE is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 25% from baseline.
[0133] 129. The method of aspect 127, wherein the TRANCE is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 50% from baseline.
[0134] 130. The method of aspect 127, wherein the TRANCE is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 100% from baseline.
[0135] 131. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interleukin-1.
[0136] 132. The method of aspect 131, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 25% from baseline.
[0137] 133. The method of aspect 131, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 50% from baseline.
[0138] 134. The method of aspect 131, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 100% from baseline.
[0139] 135. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interleukin-1.
[0140] 136. The method of aspect 135, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 25% from baseline.
[0141] 137. The method of aspect 135, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 50% from baseline.
[0142] 138. The method of aspect 135, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 100% from baseline.
[0143] 135. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interleukin-1.
[0144] 136. The method of aspect 135, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 25% from baseline.
[0145] 137. The method of aspect 135, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 50% from baseline.
[0146] 138. The method of aspect 135, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 100% from baseline.
[0147] 139. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interleukin-6.
[0148] 140. The method of aspect 139, wherein the interleukin-6 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 25% from baseline.
[0149] 141. The method of aspect 139, wherein the interleukin-6 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 50% from baseline.
[0150] 142. The method of aspect 139, wherein the interleukin-6 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 100% from baseline.
[0151] 143. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interleukin-8.
[0152] 144. The method of aspect 143, wherein the interleukin-8 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 25% from baseline.
[0153] 145. The method of aspect 143, wherein the interleukin-8 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 50% from baseline.
[0154] 146. The method of aspect 143, wherein the interleukin-8 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 100% from baseline.
[0155] 147. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interleukin-17.
[0156] 148. The method of aspect 147, wherein the interleukin-17 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 25% from baseline.
[0157] 149. The method of aspect 147, wherein the interleukin-17 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 50% from baseline.
[0158] 150. The method of aspect 147, wherein the interleukin-17 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 100% from baseline.
[0159] 151. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interleukin-18.
[0160] 152. The method of aspect 147, wherein the interleukin-18 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 25% from baseline.
[0161] 153. The method of aspect 147, wherein the interleukin-18 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 50% from baseline.
[0162] 154. The method of aspect 147, wherein the interleukin-18 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 100% from baseline.
[0163] 155. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to HMGB1.
[0164] 156. The method of aspect 155, wherein the HMGB1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 25% from baseline.
[0165] 157. The method of aspect 155, wherein the HMGB1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 50% from baseline.
[0166] 158. The method of aspect 155, wherein the HMGB1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the expression of the interleukin-10 receptor by 100% from baseline.
[0167] 159. The method of aspect 111, wherein the interferon-γ is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase the production of indoleamine 2,3-dioxygenase by 25% from baseline.
[0168] 160. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interferon-γ.
[0169] 161. The method of aspect 160, wherein the interferon-γ is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 25% from baseline levels.
[0170] 162. The method of aspect 160, wherein the interferon-γ is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 50% from baseline levels.
[0171] 163. The method of aspect 160, wherein the interferon-γ is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 100% from baseline levels.
[0172] 164. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to TNF-α.
[0173] 165. The method of aspect 164, wherein the TNF-α is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 25% from baseline levels.
[0174] 166. The method of aspect 164, wherein the TNF-α is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 50% from baseline levels.
[0175] 167. The method of aspect 164, wherein the TNF-α is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 100% from baseline levels.
[0176] 168. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to TRAIL.
[0177] 169. The method of aspect 168, wherein the TRAIL is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 25% from baseline levels.
[0178] 170. The method of aspect 168, wherein the TRAIL is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 50% from baseline levels.
[0179] 171. The method of aspect 168, wherein the TRAIL is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 100% from baseline levels.
[0180] 172. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to lymphotoxin.
[0181] 173. The method of aspect 172, wherein the lymphotoxin is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 25% from baseline levels.
[0182] 174. The method of aspect 172, wherein the lymphotoxin is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 50% from baseline levels.
[0183] 175. The method of aspect 172, wherein the lymphotoxin is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 100% from baseline levels.
[0184] 176. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to TRANCE.
[0185] 177. The method of aspect 176, wherein the TRANCE is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 25% from baseline.
[0186] 178. The method of aspect 176, wherein the TRANCE is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 50% from baseline levels.
[0187] 179. The method of aspect 176, wherein the TRANCE is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 100% from baseline levels.
[0188] 180. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interleukin-1.
[0189] 181. The method of aspect 180, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 25% from baseline levels.
[0190] 182. The method of aspect 180, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 50% from baseline levels.
[0191] 183. The method of aspect 181, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 100% from baseline levels.
[0192] 184. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interleukin-1.
[0193] 185. The method of aspect 184, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 25% from baseline levels.
[0194] 186. The method of aspect 185, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 50% from baseline levels.
[0195] 187. The method of aspect 185, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 100% from baseline levels.
[0196] 188. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interleukin-1.
[0197] 189. The method of aspect 188, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 25% from baseline levels.
[0198] 190. The method of aspect 188, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 50% from baseline levels.
[0199] 191. The method of aspect 188, wherein the interleukin-1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 100% from baseline levels.
[0200] 192. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interleukin-6.
[0201] 193. The method of aspect 192, wherein the interleukin-6 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 25% from baseline levels.
[0202] 194. The method of aspect 192, wherein the interleukin-6 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 50% from baseline levels.
[0203] 195. The method of aspect 192, wherein the interleukin-6 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 100% from baseline levels.
[0204] 196. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interleukin-8.
[0205] 197. The method of aspect 196, wherein the interleukin-8 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 25% from baseline levels.
[0206] 197. The method of aspect 196, wherein the interleukin-8 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 50% from baseline levels.
[0207] 198. The method of aspect 196, wherein the interleukin-8 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 100% from baseline levels.
[0208] 199. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interleukin-17.
[0209] 200. The method of aspect 199, wherein the interleukin-17 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 25% from baseline levels.
[0210] 202. The method of aspect 199, wherein the interleukin-17 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 50% from baseline levels.
[0211] 203. The method of aspect 199, wherein the interleukin-17 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 100% from baseline levels.
[0212] 204. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to interleukin-18.
[0213] 205. The method of aspect 204, wherein the interleukin-18 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 25% from baseline levels.
[0214] 206. The method of aspect 204, wherein the interleukin-18 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 50% from baseline levels.
[0215] 207. The method of aspect 204, wherein the interleukin-18 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 100% from baseline levels.
[0216] 208. The method of aspects 56 to 60, wherein the mesenchymal stem cells are exposed to HMGB1.
[0217] 209. The method of aspect 208, wherein the HMGB1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 25% from baseline levels.
[0218] 210. The method of aspect 208, wherein the HMGB1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 50% from baseline levels.
[0219] 211. The method of aspect 208, wherein the HMGB1 is applied to the mesenchymal stem cells at a concentration and duration sufficient to increase LIF production by 100% from baseline levels.
[0220] 212. The method of aspect 1, wherein the representative tissue cells belong to the tissue type from which their progenitor cells are expected to be generated.
[0221] 213. The method of aspect 212, wherein the tissue is selected from the following: a) kidney tissue; b) liver tissue; c) stomach tissue; d) skin tissue; e) thymus tissue; f) nerve tissue; g) hair tissue; h) eye tissue; i) lymphatic tissue; j) musculoskeletal tissue; k) bone tissue; l) endocrine tissue; m) vascular tissue; n) hematopoietic tissue; o) colon tissue; p) heart tissue; q) muscle tissue; r) nail tissue; s) cartilage tissue; t) pancreatic tissue; u) bladder tissue; v) penis tissue; w) testicular tissue; x) prostate tissue; y) ovarian tissue; z) fallopian tube tissue; aa) digestive tissue; and ab) glandular tissue.
[0222] 214. The method of aspect 213, wherein the representative tissue is prepared by the following steps: first, decellularizing the tissue to obtain a matrix from the tissue, and then seeding cells into the tissue.
[0223] 215. The method of aspect 214, wherein the representative tissue is treated with a cellular stressor.
[0224] 216. The method of aspect 215, wherein the conditioned medium is obtained from the representative tissue treated with the cellular stressor.
[0225] 217. The method of aspect 216, wherein the conditioned medium is added to the pluripotent stem cells.
[0226] 218. The method of aspect 217, wherein the conditioned medium is added together with the "differentiation adjuvant" to the pluripotent stem cells.
[0227] 219. The method of aspect 218, wherein the differentiation adjuvant is tissue-specific.
[0228] 220. The method of aspect 218, wherein the differentiation adjuvant is tissue-nonspecific.
[0229] 221. The method of aspect 214, wherein the tissue is decellularized by using a solvent treatment.
[0230] 222. The method of aspect 214, wherein the decellularized tissue retains anatomical features.
[0231] 223. The method of aspect 214, wherein the decellularized tissue is seeded with pluripotent stem cells.
[0232] 224. The method of aspect 214, wherein the decellularized tissue is inoculated with differentiated progenitor cells.
[0233] 225. The method of aspect 214, wherein the decellularized tissue is seeded with mesenchymal stem cells.
[0234] 226. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells.
[0235] 227. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using a c-kit screening method.
[0236] 228. The method of aspect 227, wherein the c-kit screening is performed via immune isolation.
[0237] 229. The method of aspect 227, wherein the c-kit screening is performed via immunosurgery.
[0238] 230. The method of aspect 227, wherein the c-kit screening is performed by magnetically activated cell sorting.
[0239] 231. The method of aspect 227, wherein the c-kit screening is performed by fluorescence-activated cell sorting.
[0240] 232. The method of aspect 227, wherein the c-kit screening is performed by positive selection.
[0241] 233. The method of aspect 227, wherein the c-kit screening is performed by negative selection.
[0242] 234. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using a VEGF receptor screening method.
[0243] 235. The method of aspect 234, wherein the VEGF receptor screening is performed via immune isolation.
[0244] 236. The method of aspect 234, wherein the VEGF receptor screening is performed via immunosurgery.
[0245] 237. The method of aspect 227, wherein the VEGF receptor screening is performed by magnetically activated cell sorting.
[0246] 238. The method of aspect 234, wherein the VEGF receptor screening is performed by fluorescence-activated cell sorting.
[0247] 239. The method of aspect 234, wherein the VEGF receptor screening is performed by positive selection.
[0248] 240. The method of aspect 234, wherein the VEGF receptor screening is performed by negative selection.
[0249] 241. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using an aldehyde dehydrogenase screening method.
[0250] 242. The method of aspect 241, wherein the aldehyde dehydrogenase screening is performed by immune isolation.
[0251] 243. The method of aspect 241, wherein the aldehyde dehydrogenase screening is performed via immunosurgery.
[0252] 244. The method of aspect 241, wherein the aldehyde dehydrogenase screening is performed by magnetically activated cell sorting.
[0253] 245. The method of aspect 241, wherein the aldehyde dehydrogenase screening is performed by fluorescence-activated cell sorting.
[0254] 246. The method of aspect 241, wherein the aldehyde dehydrogenase screening is performed by positive selection.
[0255] 247. The method of aspect 241, wherein the aldehyde dehydrogenase screening is performed by negative selection.
[0256] 248. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using a CD133 screening method.
[0257] 249. The method of aspect 248, wherein the CD133 screening is performed via immune isolation.
[0258] 250. The method of aspect 248, wherein the CD133 screening is performed via immunosurgery.
[0259] 251. The method of aspect 248, wherein the CD133 screening is performed by magnetically activated cell sorting.
[0260] 252. The method of aspect 248, wherein the CD133 screening is performed by fluorescence-activated cell sorting.
[0261] 253. The method of aspect 248, wherein the CD133 screening is performed by positive selection.
[0262] 254. The method of aspect 248, wherein the CD133 screening is performed by negative selection.
[0263] 255. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using a CD34 screening method.
[0264] 256. The method of aspect 255, wherein the CD34 screening is performed via immune isolation.
[0265] 257. The method of aspect 255, wherein the CD34 screening is performed via immunosurgery.
[0266] 258. The method of aspect 255, wherein the CD34 screening is performed by magnetically activated cell sorting.
[0267] 259. The method of aspect 255, wherein the CD34 screening is performed by fluorescence-activated cell sorting.
[0268] 260. The method of aspect 255, wherein the CD34 screening is performed by positive selection.
[0269] 261. The method of aspect 255, wherein the CD34 screening is performed by negative selection.
[0270] 262. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using a CD73 screening method.
[0271] 263. The method of aspect 262, wherein the CD73 screening is performed via immune isolation.
[0272] 264. The method of aspect 262, wherein the CD73 screening is performed via immunosurgery.
[0273] 265. The method of aspect 262, wherein the CD73 screening is performed by magnetically activated cell sorting.
[0274] 266. The method of aspect 262, wherein the CD73 screening is performed by fluorescence-activated cell sorting.
[0275] 267. The method of aspect 262, wherein the CD73 screening is performed by positive selection.
[0276] 268. The method of aspect 262, wherein the CD73 screening is performed by negative selection.
[0277] 269. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using a c-met screening method.
[0278] 270. The method of aspect 269, wherein the c-met screening is performed via immune isolation.
[0279] 271. The method of aspect 269, wherein the c-met screening is performed via immunosurgery.
[0280] 272. The method of aspect 269, wherein the c-met screening is performed by magnetically activated cell sorting.
[0281] 273. The method of aspect 269, wherein the c-met screening is performed by fluorescence-activated cell sorting.
[0282] 274. The method of aspect 269, wherein the c-met screening is performed by positive selection.
[0283] 275. The method of aspect 269, wherein the c-met screening is performed by negative selection.
[0284] 276. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using a PD-L1 screening method.
[0285] 277. The method of aspect 276, wherein the PD-L1 screening is performed via immune isolation.
[0286] 278. The method of aspect 276, wherein the PD-L1 screening is performed via immunosurgery.
[0287] 279. The method of aspect 276, wherein the PD-L1 screening is performed by magnetically activated cell sorting.
[0288] 280. The method of aspect 276, wherein the PD-L1 screening is performed by fluorescence-activated cell sorting.
[0289] 281. The method of aspect 276, wherein the PD-L1 screening is performed by positive selection.
[0290] 282. The method of aspect 276, wherein the PD-L1 screening is performed by negative selection.
[0291] 283. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using a c-mpl screening method.
[0292] 284. The method of aspect 283, wherein the c-mpl screening is performed by immune isolation.
[0293] 285. The method of aspect 283, wherein the c-mpl screening is performed via immunosurgery.
[0294] 286. The method of aspect 283, wherein the c-mpl screening is performed by magnetically activated cell sorting.
[0295] 287. The method of aspect 283, wherein the c-mpl screening is performed by fluorescence-activated cell sorting.
[0296] 288. The method of aspect 283, wherein the c-mpl screening is performed by positive selection.
[0297] 289. The method of aspect 283, wherein the c-mpl screening is performed by negative selection.
[0298] 290. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using a PIM-1 screening method.
[0299] 291. The method of aspect 290, wherein the pim-1 screening is performed by immune isolation.
[0300] 292. The method of aspect 290, wherein the pim-1 screening is performed via immunosurgery.
[0301] 293. The method of aspect 290, wherein the pim-1 screening is performed by magnetically activated cell sorting.
[0302] 294. The method of aspect 290, wherein the pim-1 screening is performed by fluorescence-activated cell sorting.
[0303] 295. The method of aspect 290, wherein the pim-1 screening is performed by positive selection.
[0304] 296. The method of aspect 290, wherein the pim-1 screening is performed by negative selection.
[0305] 297. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using an interleukin-1 receptor screening method.
[0306] 298. The method of aspect 297, wherein the interleukin-1 receptor screening is performed via immune isolation.
[0307] 299. The method of aspect 297, wherein the interleukin-1 receptor screening is performed via immunosurgery.
[0308] 300. The method of aspect 297, wherein the interleukin-1 receptor screening is performed by magnetically activated cell sorting.
[0309] 301. The method of aspect 297, wherein the interleukin-1 receptor screening is performed by fluorescence-activated cell sorting.
[0310] 302. The method of aspect 297, wherein the interleukin-1 receptor screening is performed by positive selection.
[0311] 303. The method of aspect 297, wherein the interleukin-1 receptor screening is performed by negative selection.
[0312] 304. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using an interleukin-6 receptor screening method.
[0313] 305. The method of aspect 304, wherein the interleukin-6 receptor screening is performed via immune isolation.
[0314] 306. The method of aspect 304, wherein the interleukin-6 receptor screening is performed via immunosurgery.
[0315] 307. The method of aspect 304, wherein the interleukin-6 receptor screening is performed by magnetically activated cell sorting.
[0316] 308. The method of aspect 304, wherein the interleukin-6 receptor screening is performed by fluorescence-activated cell sorting.
[0317] 309. The method of aspect 304, wherein the interleukin-6 receptor screening is performed by positive selection.
[0318] 310. The method of aspect 304, wherein the interleukin-6 receptor screening is performed by negative selection.
[0319] 311. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using an interleukin-3 receptor screening method.
[0320] 312. The method of aspect 311, wherein the interleukin-3 receptor screening is performed via immune isolation.
[0321] 313. The method of aspect 311, wherein the interleukin-3 receptor screening is performed via immunosurgery.
[0322] 314. The method of aspect 311, wherein the interleukin-3 receptor screening is performed by magnetically activated cell sorting.
[0323] 315. The method of aspect 311, wherein the interleukin-3 receptor screening is performed by fluorescence-activated cell sorting.
[0324] 316. The method of aspect 311, wherein the interleukin-3 receptor screening is performed by positive selection.
[0325] 317. The method of aspect 311, wherein the interleukin-3 receptor screening is performed by negative selection.
[0326] 318. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using an interleukin-11 receptor screening method.
[0327] 319. The method of aspect 318, wherein the interleukin-11 receptor screening is performed via immune isolation.
[0328] 320. The method of aspect 318, wherein the interleukin-11 receptor screening is performed via immunosurgery.
[0329] 321. The method of aspect 318, wherein the interleukin-11 receptor screening is performed by magnetically activated cell sorting.
[0330] 322. The method of aspect 318, wherein the interleukin-11 receptor screening is performed by fluorescence-activated cell sorting.
[0331] 323. The method of aspect 318, wherein the interleukin-11 receptor screening is performed by positive selection.
[0332] 324. The method of aspect 318, wherein the interleukin-11 receptor screening is performed by negative selection.
[0333] 325. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using an EGF receptor screening method.
[0334] 326. The method of aspect 325, wherein the EGF receptor screening is performed via immune isolation.
[0335] 327. The method of aspect 325, wherein the EGF receptor screening is performed via immunosurgery.
[0336] 328. The method of aspect 325, wherein the EGF receptor screening is performed by magnetically activated cell sorting.
[0337] 329. The method of aspect 325, wherein the EGF receptor screening is performed by fluorescence-activated cell sorting.
[0338] 330. The method of aspect 325, wherein the EGF receptor screening is performed by positive selection.
[0339] 331. The method of aspect 325, wherein the EGF receptor screening is performed by negative selection.
[0340] 332. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using a PDGF receptor screening method.
[0341] 333. The method of aspect 332, wherein the PDGF receptor screening is performed via immune isolation.
[0342] 334. The method of aspect 332, wherein the PDGF receptor screening is performed via immunosurgery.
[0343] 335. The method of aspect 332, wherein the PDGF receptor screening is performed by magnetically activated cell sorting.
[0344] 336. The method of aspect 332, wherein the PDGF receptor screening is performed by fluorescence-activated cell sorting.
[0345] 337. The method of aspect 332, wherein the PDGF receptor screening is performed by positive selection.
[0346] 338. The method of aspect 332, wherein the PDGF receptor screening is performed by negative selection.
[0347] 339. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using an FGF-1 receptor screening method.
[0348] 340. The method of aspect 339, wherein the FGF-1 receptor screening is performed via immune isolation.
[0349] 341. The method of aspect 339, wherein the FGF-1 receptor screening is performed via immunosurgery.
[0350] 342. The method of aspect 339, wherein the FGF-1 receptor screening is performed by magnetically activated cell sorting.
[0351] 343. The method of aspect 339, wherein the FGF-1 receptor screening is performed by fluorescence-activated cell sorting.
[0352] 344. The method of aspect 339, wherein the FGF-1 receptor screening is performed by positive selection.
[0353] 345. The method of aspect 339, wherein the FGF-1 receptor screening is performed by negative selection.
[0354] 346. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using an FGF-1 receptor screening method.
[0355] 347. The method of aspect 346, wherein the FGF-1 receptor screening is performed via immune isolation.
[0356] 348. The method of aspect 346, wherein the FGF-1 receptor screening is performed via immunosurgery.
[0357] 349. The method of aspect 346, wherein the FGF-1 receptor screening is performed by magnetically activated cell sorting.
[0358] 350. The method of aspect 346, wherein the FGF-1 receptor screening is performed by fluorescence-activated cell sorting.
[0359] 351. The method of aspect 346, wherein the FGF-1 receptor screening is performed by positive selection.
[0360] 352. The method of aspect 346, wherein the FGF-1 receptor screening is performed by negative selection.
[0361] 353. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using an FGF-2 receptor screening method.
[0362] 354. The method of aspect 353, wherein the FGF-2 receptor screening is performed via immune isolation.
[0363] 355. The method of aspect 353, wherein the FGF-2 receptor screening is performed via immunosurgery.
[0364] 356. The method of aspect 353, wherein the FGF-2 receptor screening is performed by magnetically activated cell sorting.
[0365] 357. The method of aspect 353, wherein the FGF-2 receptor screening is performed by fluorescence-activated cell sorting.
[0366] 358. The method of aspect 353, wherein the FGF-2 receptor screening is performed by positive selection.
[0367] 359. The method of aspect 353, wherein the FGF-2 receptor screening is performed by negative selection.
[0368] 360. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using a galactolectin-3 receptor screening method.
[0369] 361. The method of aspect 360, wherein the galactoglobulin-3 receptor screening is performed via immune isolation.
[0370] 362. The method of aspect 361, wherein the galactoglobulin-3 receptor screening is performed via immunosurgery.
[0371] 363. The method of aspect 361, wherein the galactoglobulin-3 receptor screening is performed by magnetically activated cell sorting.
[0372] 364. The method of aspect 361, wherein the galactoglobulin-3 receptor screening is performed by fluorescence-activated cell sorting.
[0373] 365. The method of aspect 361, wherein the galactoglobulin-3 receptor screening is performed by positive selection.
[0374] 366. The method of aspect 361, wherein the galactoglobulin-3 receptor screening is performed by negative selection.
[0375] 367. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using a Jagged receptor screening method.
[0376] 368. The method of aspect 367, wherein the Jagged receptor screening is performed via immune isolation.
[0377] 369. The method of aspect 367, wherein the Jagged receptor screening is performed via immunosurgery.
[0378] 370. The method of aspect 367, wherein the Jagged receptor screening is performed by magnetically activated cell sorting.
[0379] 371. The method of aspect 367, wherein the Jagged receptor screening is performed by fluorescence-activated cell sorting.
[0380] 372. The method of aspect 367, wherein the Jagged receptor screening is performed by positive selection.
[0381] 373. The method of aspect 367, wherein the Jagged receptor screening is performed by negative selection.
[0382] 374. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using a GDF-11 receptor screening method.
[0383] 375. The method of aspect 374, wherein the GDF-11 receptor screening is performed via immune isolation.
[0384] 376. The method of aspect 374, wherein the GDF-11 receptor screening is performed via immunosurgery.
[0385] 377. The method of aspect 374, wherein the GDF-11 receptor screening is performed by magnetically activated cell sorting.
[0386] 378. The method of aspect 374, wherein the GDF-11 receptor screening is performed by fluorescence-activated cell sorting.
[0387] 379. The method of aspect 374, wherein the GDF-11 receptor screening is performed by positive selection.
[0388] 380. The method of aspect 374, wherein the GDF-11 receptor screening is performed by negative selection.
[0389] 381. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using an angiopoietin receptor screening method.
[0390] 382. The method of aspect 381, wherein the angiopoietin receptor screening is performed via immune isolation.
[0391] 383. The method of aspect 381, wherein the angiopoietin receptor screening is performed via immunosurgery.
[0392] 384. The method of aspect 381, wherein the angiopoietin receptor screening is performed by magnetically activated cell sorting.
[0393] 385. The method of aspect 381, wherein the angiopoietin receptor screening is performed by fluorescence-activated cell sorting.
[0394] 386. The method of aspect 381, wherein the angiopoietin receptor screening is performed by positive selection.
[0395] 387. The method of aspect 381, wherein the angiopoietin receptor screening is performed by negative selection.
[0396] 388. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using a TGF-β receptor screening method.
[0397] 389. The method of aspect 388, wherein the TGF-β receptor screening is performed via immune isolation.
[0398] 390. The method of aspect 388, wherein the TGF-β receptor screening is performed via immunosurgery.
[0399] 391. The method of aspect 388, wherein the TGF-β receptor screening is performed by magnetically activated cell sorting.
[0400] 392. The method of aspect 388, wherein the TGF-β receptor screening is performed by fluorescence-activated cell sorting.
[0401] 393. The method of aspect 388, wherein the TGF-β receptor screening is performed by positive selection.
[0402] 394. The method of aspect 388, wherein the TGF-β receptor screening is performed by negative selection.
[0403] 395. The method of aspect 214, wherein the decellularized tissue is seeded with tissue-specific progenitor cells, the tissue-specific progenitor cells being isolated from cells of the desired tissue using an endothelial receptor screening method.
[0404] 396. The method of aspect 395, wherein the endothelial receptor screening is performed via immune isolation.
[0405] 397. The method of aspect 395, wherein the endothelial receptor screening is performed via immunosurgery.
[0406] 398. The method of aspect 395, wherein the endothelial receptor screening is performed by magnetically activated cell sorting.
[0407] 399. The method of aspect 395, wherein the endothelial receptor screening is performed by fluorescence-activated cell sorting.
[0408] 400. The method of aspect 395, wherein the endothelial receptor screening is performed by positive selection.
[0409] 401. The method of aspect 395, wherein the endothelial receptor screening is performed by negative selection.
[0410] 402. The method of aspects 227 to 401, wherein the tissue-specific progenitor cells expand under conditions without significant differentiation.
[0411] 403. The method of aspect 402, wherein the expansion of the tissue-specific progenitor cells under conditions of no significant differentiation is achieved by culturing them in the presence of one or more ROCK inhibitors.
[0412] 404. The method of aspect 402, wherein the expansion of the tissue-specific progenitor cells under conditions of no significant differentiation is achieved by culturing them in the presence of one or more histone deacetylase inhibitors.
[0413] 405. The method of aspects 225 to 401, wherein the tissue-specific progenitor cells are expanded by means capable of improving the survival rate of the cells.
[0414] 406. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with hypoxia.
[0415] 407. The method of aspect 406, wherein the cells are exposed to an oxygen atmosphere of 0.1% to 4% for 5 minutes to 8 hours.
[0416] 408. The method of aspect 406, wherein the cells are exposed to an oxygen atmosphere of 0.5% to 4% for 5 minutes to 8 hours.
[0417] 409. The method of aspect 406, wherein the cells are exposed to an oxygen atmosphere of 1% to 4% for 5 minutes to 8 hours.
[0418] 410. The method of aspect 406, wherein the cells are exposed to an oxygen atmosphere of 2% to 4% for 5 minutes to 8 hours.
[0419] 411. The method of aspect 406, wherein the cells are exposed to an oxygen atmosphere of 2% to 4% for 1 to 8 hours.
[0420] 412. The method of aspect 406, wherein the cells are exposed to an oxygen atmosphere of 2% to 4% for 2 to 8 hours.
[0421] 413. The method of aspect 406, wherein the cells are exposed to an oxygen atmosphere of 2% to 4% for 4 to 8 hours.
[0422] 414. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase the bcl-2 level by 10% or more from the baseline value.
[0423] 415. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase the bcl-2 level by 20% or more from the baseline value.
[0424] 416. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase the bcl-2 level by 100% or more from the baseline value.
[0425] 417. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase survivin levels by 10% or more from baseline.
[0426] 418. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase survivin levels by 20% or more from baseline.
[0427] 419. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase survivin levels by 100% or more from baseline.
[0428] 420. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase livin levels by 10% or more from baseline.
[0429] 421. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase livin levels by 20% or more from baseline.
[0430] 339. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase livin levels by 100% or more from baseline.
[0431] 340. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase the IAP-1 level by 10% or more from the baseline value.
[0432] 341. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase the IAP-1 level by 20% or more from the baseline value.
[0433] 342. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase the IAP-1 level by 100% or more from the baseline value.
[0434] 343. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase the bcl-2xL level by 10% or more from the baseline value.
[0435] 344. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase the bcl-2xL level by 20% or more from the baseline value.
[0436] 345. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with hydrogen gas, wherein the concentration of hydrogen gas used and the treatment time are sufficient to increase the bcl-2xL level by 100% or more from the baseline value.
[0437] 346. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with argon gas, wherein the concentration of argon gas used and the treatment time are sufficient to increase the bcl-2 level by 10% or more from the baseline value.
[0438] 347. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with argon gas, wherein the concentration of argon gas used and the treatment time are sufficient to increase the bcl-2 level by 20% or more from the baseline value.
[0439] 348. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with argon gas, wherein the concentration of argon gas used and the treatment time are sufficient to increase the bcl-2 level by 100% or more from the baseline value.
[0440] 349. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with argon gas, wherein the concentration of argon gas used and the treatment time are sufficient to increase survivin levels by 10% or more from baseline.
[0441] 350. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with argon gas, wherein the concentration of argon gas used and the treatment time are sufficient to increase survivin levels by 20% or more from baseline.
[0442] 351. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with argon gas, wherein the concentration of argon gas used and the treatment time are sufficient to increase survivin levels by 100% or more from baseline.
[0443] 352. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with argon gas, wherein the concentration of argon gas used and the treatment time are sufficient to increase livin levels by 10% or more from baseline.
[0444] 353. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with argon gas, the concentration of argon gas used and the treatment time being sufficient to increase livin levels by 20% or more from baseline.
[0445] 354. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with argon gas, wherein the concentration of argon gas used and the treatment time are sufficient to increase livin levels by 100% or more from baseline.
[0446] 355. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with argon gas, wherein the concentration of argon gas used and the treatment time are sufficient to increase the IAP-1 level by 10% or more from the baseline value.
[0447] 356. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with argon gas, wherein the concentration of argon gas used and the treatment time are sufficient to increase the IAP-1 level by 20% or more from the baseline value.
[0448] 357. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with argon gas, wherein the concentration of argon gas used and the treatment time are sufficient to increase the IAP-1 level by 100% or more from the baseline value.
[0449] 358. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with argon gas, wherein the concentration of argon gas used and the treatment time are sufficient to increase the bcl-2xL level by 10% or more from the baseline value.
[0450] 359. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with argon gas, wherein the concentration of argon gas used and the treatment time are sufficient to increase the bcl-2xL level by 20% or more from the baseline value.
[0451] 360. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with argon gas, wherein the concentration of argon gas used and the treatment time are sufficient to increase the bcl-2xL level by 100% or more from the baseline value.
[0452] 361. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase the bcl-2 level by 10% or more from the baseline value.
[0453] 362. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase the bcl-2 level by 20% or more from the baseline value.
[0454] 363. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase the bcl-2 level by 100% or more from the baseline value.
[0455] 364. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase survivin levels by 10% or more from baseline.
[0456] 365. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase survivin levels by 20% or more from baseline.
[0457] 366. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase survivin levels by 100% or more from baseline.
[0458] 367. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase livin levels by 10% or more from baseline.
[0459] 368. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase livin levels by 20% or more from baseline.
[0460] 369. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase livin levels by 100% or more from baseline.
[0461] 370. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase IAP-1 levels by 10% or more from baseline.
[0462] 371. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase IAP-1 levels by 20% or more from baseline.
[0463] 372. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase IAP-1 levels by 100% or more from baseline.
[0464] 373. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase the bcl-2xL level by 10% or more from the baseline value.
[0465] 374. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase the bcl-2xL level by 20% or more from the baseline value.
[0466] 375. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with N-acetylcysteine, wherein the concentration of N-acetylcysteine used and the duration of treatment are sufficient to increase the bcl-2xL level by 100% or more from the baseline value.
[0467] 376. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase the bcl-2 level by 10% or more from the baseline value.
[0468] 377. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase the bcl-2 level by 20% or more from the baseline value.
[0469] 378. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase the bcl-2 level by 100% or more from the baseline value.
[0470] 379. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase survivin levels by 10% or more from baseline.
[0471] 380. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase survivin levels by 20% or more from baseline.
[0472] 381. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase survivin levels by 100% or more from baseline.
[0473] 382. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase livin levels by 10% or more from baseline.
[0474] 383. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase livin levels by 20% or more from baseline.
[0475] 384. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase livin levels by 100% or more from baseline.
[0476] 385. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase IAP-1 levels by 10% or more from baseline.
[0477] 386. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase IAP-1 levels by 20% or more from baseline.
[0478] 387. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase IAP-1 levels by 100% or more from baseline.
[0479] 388. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase the bcl-2xL level by 10% or more from the baseline value.
[0480] 389. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase the bcl-2xL level by 20% or more from the baseline value.
[0481] 390. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with erythropoietin, wherein the concentration of erythropoietin used and the duration of treatment are sufficient to increase the bcl-2xL level by 100% or more from the baseline value.
[0482] 391. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with FGF-1.
[0483] 392. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with Z-VAD-FMK.
[0484] 393. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with Z-VAD-(OME)-FMK.
[0485] 394. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with Q-VD-OPH.
[0486] 395. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with Belnacasan.
[0487] 396. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with Z-DEVD-FMK.
[0488] 397. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with Ac-DEVD-FMK.
[0489] 398. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with dehydrocorydaline.
[0490] 399. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with 714-X.
[0491] 400. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with siRNA targeting bcl-2Xs.
[0492] 401. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with antisense oligonucleotides targeting bcl-2Xs.
[0493] 402. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with a hammerhead ribozyme targeting bcl-2Xs.
[0494] 403. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with gene editing targeting bcl-2Xs.
[0495] 404. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with siRNA targeting caspase-3.
[0496] 405. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with antisense oligonucleotides targeting caspase-3.
[0497] 406. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with a hammerhead ribozyme targeting caspase-3.
[0498] 407. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with gene editing targeting caspase-3.
[0499] 408. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with siRNA targeting caspase-8.
[0500] 409. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with an antisense oligonucleotide targeting caspase-8.
[0501] 410. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with a hammerhead ribozyme targeting caspase-8.
[0502] 411. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with gene editing targeting caspase-8.
[0503] 412. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with siRNA targeting caspase-9.
[0504] 413. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with an antisense oligonucleotide targeting caspase-9.
[0505] 414. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with a hammerhead ribozyme targeting caspase-9.
[0506] 415. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with gene editing targeting caspase-9.
[0507] 416. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with siRNA targeting Bax.
[0508] 417. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with antisense oligonucleotides targeting Bax.
[0509] 418. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with a hammerhead ribozyme targeting Bax.
[0510] 419. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with gene editing targeting Bax.
[0511] 420. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with siRNA targeting Bid.
[0512] 421. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with antisense oligonucleotides targeting Bid.
[0513] 422. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with a hammerhead ribozyme targeting Bid.
[0514] 423. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with gene editing targeting Bid.
[0515] 424. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with siRNA targeting Hrk.
[0516] 425. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with antisense oligonucleotides targeting Hrk.
[0517] 426. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with a hammerhead ribozyme targeting Hrk.
[0518] 427. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with gene editing targeting Hrk.
[0519] 428. The method of aspect 405, wherein the improvement in survival is achieved by pretreating cells with an NF-κB stimulator.
[0520] 429. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with minocycline.
[0521] 430. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with doxycycline.
[0522] 431. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with creatinine.
[0523] 432. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with dichloroacetate.
[0524] 433. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with coenzyme Q10.
[0525] 434. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with lipoic acid.
[0526] 435. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with retinoic acid.
[0527] 436. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with all-trans retinoic acid.
[0528] 437. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with vitamin D3.
[0529] 438. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with cystamine.
[0530] 439. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with buxiramine.
[0531] 440. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with riluzole.
[0532] 441. The method of aspect 405, wherein the improvement in survival rate is achieved by pretreating cells with lindera lactone.
[0533] 442. The method of aspects 225 to 401, wherein the tissue-specific progenitor cells are expanded by administration of a histone deacetylase inhibitor.
[0534] 443. The method of aspect 442, wherein the histone deacetylase inhibitor is a siRNA that targets one or more histone deacetylases.
[0535] 444. The method of aspect 442, wherein the histone deacetylase inhibitor is a microRNA that targets one or more histone deacetylases.
[0536] 445. The method of aspect 442, wherein the histone deacetylase inhibitor is an antisense oligonucleotide that targets one or more histone deacetylases.
[0537] 446. The method of aspect 442, wherein the histone deacetylase inhibitor is a decoy oligonucleotide that targets one or more histone deacetylases.
[0538] 447. The method of aspect 442, wherein the histone deacetylase inhibitor is a hammerhead ribozyme that targets one or more histone deacetylases.
[0539] 448. The method of aspect 442, wherein the histone deacetylase inhibitor is sulforaphane.
[0540] 449. The method of aspect 442, wherein the histone deacetylase inhibitor is valproic acid.
[0541] 450. The method of aspect 442, wherein the histone deacetylase inhibitor is trichosuccinimide A.
[0542] 451. The method of aspect 442, wherein the histone deacetylase inhibitor is phenyl butyrate.
[0543] 452. The method of aspect 442, wherein the histone deacetylase inhibitor is vorinostat.
[0544] 453. The method of aspect 442, wherein the histone deacetylase inhibitor is romidesin.
[0545] 454. The method of aspect 442, wherein the histone deacetylase inhibitor is pabisostat.
[0546] 455. The method of aspect 442, wherein the histone deacetylase inhibitor is belistat.
[0547] 456. The method of aspects 225 to 401, wherein the tissue-specific progenitor cells are expanded by treatment with an NF-κB inhibitor.
[0548] 457. The method of aspect 456, wherein the NF-κB inhibitor is N-acetylcysteine.
[0549] 458. The method of aspect 456, wherein the NF-κB inhibitor is ascorbic acid.
[0550] 459. The method of aspect 456, wherein the NF-κB inhibitor is α-lipoic acid.
[0551] 460. The method of aspects 225 to 401, wherein the tissue-specific progenitor cells are expanded by treatment with growth factors.
[0552] 461. The method of aspect 460, wherein the growth factor is FGF-1.
[0553] 462. The method of aspect 460, wherein the growth factor is FGF-2.
[0554] 463. The method of aspect 460, wherein the growth factor is FGF-5.
[0555] 464. The method of aspect 460, wherein the growth factor is PDGF.
[0556] 465. The method of aspect 460, wherein the growth factor is PDGF-BB.
[0557] 466. The method of aspect 460, wherein the growth factor is angiopoietin.
[0558] 467. The method of aspect 460, wherein the growth factor is a cobra venom factor.
[0559] 468. The method of aspect 460, wherein the growth factor is complement component C1q.
[0560] 469. The method of aspect 460, wherein the growth factor is complement component C3a.
[0561] 470. The method of aspect 460, wherein the growth factor is complement component C5a.
[0562] 471. The method of aspect 460, wherein the growth factor is VEGF.
[0563] 472. The method of aspect 460, wherein the growth factor is VEGF-C.
[0564] 473. The method of aspect 460, wherein the growth factor is EGF.
[0565] 474. The method of aspect 460, wherein the growth factor is FGF-1.
[0566] 475. The method of aspect 460, wherein the growth factor is FGF-2.
[0567] 476. The method of aspect 460, wherein the growth factor is FGF-5.
[0568] 477. The method of aspect 460, wherein the growth factor is IGF.
[0569] 478. The method of aspect 460, wherein the growth factor is Klotho.
[0570] 479. The method of aspect 460, wherein the growth factor is angiopoietin.
[0571] 480. The method of aspect 460, wherein the growth factor is TGF-β.
[0572] 481. The method of aspect 460, wherein the growth factor is endothelial linkerin.
[0573] 482. The method of aspect 460, wherein the growth factor is NGF.
[0574] 483. The method of aspect 460, wherein the growth factor is HGF.
[0575] 484. The method of aspect 460, wherein the growth factor is insulin.
[0576] 485. The method of aspect 460, wherein the growth factor is erythropoietin.
[0577] 486. The method of aspect 460, wherein the growth factor is protein C.
[0578] 487. The method of aspect 460, wherein the growth factor is activating protein C.
[0579] 488. The method of aspect 460, wherein the growth factor is insulin-like growth factor binding protein.
[0580] 489. The method of aspect 460, wherein the growth factor is somatostatin.
[0581] 490. The method of aspect 460, wherein the growth factor is annexin-V.
[0582] 491. The method of aspect 460, wherein the growth factor is IL-3.
[0583] 492. The method of aspect 460, wherein the growth factor is IL-4.
[0584] 493. The method of aspect 460, wherein the growth factor is IL-6.
[0585] 494. The method of aspect 460, wherein the growth factor is IL-8.
[0586] 495. The method of aspect 460, wherein the growth factor is IL-10.
[0587] 496. The method of aspect 460, wherein the growth factor is IL-12.
[0588] 497. The method of aspect 460, wherein the growth factor is IL-20.
[0589] 498. The method of aspect 460, wherein the growth factor is IL-22.
[0590] 499. The method of aspect 460, wherein the growth factor is IL-37.
[0591] 500. The method of aspect 460, wherein the growth factor is IL-38.
[0592] 501. The method of aspects 225 to 401, wherein the tissue-specific progenitor cells are expanded by using MMP3 treatment.
[0593] 502. The method of aspects 225 to 401, wherein the tissue-specific progenitor cells are expanded by using MMP5 treatment.
[0594] 503. The method of aspects 225 to 401, wherein the tissue-specific progenitor cells are expanded by using MMP7 treatment.
[0595] 504. The method of aspects 225 to 401, wherein the tissue-specific progenitor cells are expanded by using MMP9 treatment.
[0596] 505. The method of aspects 225 to 401, wherein the tissue-specific progenitor cells are expanded by treatment with MMP13.
[0597] 506. A method for generating heart-specific progenitor cells by the following steps: a) obtaining a pluripotent stem cell population; b) treating the pluripotent stem cell population with one or more cardiac differentiation media; c) extracting cardiac progenitor cells from the culture of the pluripotent stem cell population treated with the cardiac differentiation media; d) expanding the cardiac progenitor cells; and e) cryopreserving the cardiac progenitor cells.
[0598] 507. The method of aspect 1, wherein the cardiac differentiation medium is a conditioned medium derived from a cardiac progenitor cell line.
[0599] 508. The method of aspect 507, wherein the cardiac progenitor cell line is immortalized.
[0600] 509. The method of aspect 508, wherein the immortalization is achieved by treatment with a reagent that increases hTERT expression.
[0601] 510. The method of aspect 509, wherein after the treatment to increase hTERT expression, transfection is performed with one or more immortalized genes.
[0602] 511. The method of aspect 510, wherein the treatment that increases hTERT is hypoxia.
[0603] 512. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of HGF-1 by more than 25% from the baseline level.
[0604] 513. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of HGF-1 by more than 50% from the baseline level.
[0605] 514. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of HGF-1 by more than 100% from the baseline level.
[0606] 515. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of FGF-1 by more than 25% from the baseline level.
[0607] 516. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of FGF-1 by more than 50% from the baseline level.
[0608] 517. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of FGF-1 by more than 100% from the baseline level.
[0609] 518. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of FGF-2 by more than 25% from the baseline level.
[0610] 519. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of FGF-2 by more than 50% from the baseline level.
[0611] 520. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of FGF-2 by more than 100% from the baseline level.
[0612] 521. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase EGF production by more than 25% from baseline levels.
[0613] 522. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase EGF production by more than 50% from baseline levels.
[0614] 523. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase EGF production by more than 100% from baseline levels.
[0615] 524. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of bimodal proteins by more than 25% from baseline levels.
[0616] 525. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of bimodal proteins by more than 50% from baseline levels.
[0617] 526. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of bimodal proteins by more than 100% from baseline levels.
[0618] 527. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of TGF-β by more than 25% from the baseline level.
[0619] 528. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of TGF-β by more than 50% from the baseline level.
[0620] 529. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of TGF-β by more than 100% from the baseline level.
[0621] 530. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of endotheliin by more than 25% from baseline.
[0622] 531. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of endothelin by more than 50% from baseline.
[0623] 532. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of endothelial linkerin by more than 100% from the baseline level.
[0624] 533. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase VEGF production by more than 25% from baseline levels.
[0625] 534. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase VEGF production by more than 50% from baseline levels.
[0626] 535. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase VEGF production by more than 100% from baseline levels.
[0627] 536. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of IGF by more than 25% from the baseline level.
[0628] 537. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of IGF by more than 50% from the baseline level.
[0629] 538. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of IGF by more than 100% from the baseline level.
[0630] 539. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of galactolectin-1 by more than 25% from the baseline level.
[0631] 540. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of galactolectin-1 by more than 50% from the baseline level.
[0632] 541. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of galactolectin-1 by more than 100% from the baseline level.
[0633] 542. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of galactolectin-3 by more than 25% from the baseline level.
[0634] 543. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of galactolectin-3 by more than 50% from the baseline level.
[0635] 544. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of galactolectin-3 by more than 100% from the baseline level.
[0636] 545. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of galactolectin-9 by more than 25% from the baseline level.
[0637] 546. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of galactolectin-9 by more than 50% from the baseline level.
[0638] 547. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of galactolectin-9 by more than 100% from the baseline level.
[0639] 548. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of MMP-3 by more than 25% from the baseline level.
[0640] 549. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of MMP-3 by more than 50% from the baseline level.
[0641] 550. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of MMP-3 by more than 100% from the baseline level.
[0642] 551. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of MMP-9 by more than 25% from the baseline level.
[0643] 552. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of MMP-9 by more than 50% from the baseline level.
[0644] 553. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of MMP-9 by more than 100% from the baseline level.
[0645] 554. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of angiopoietin by more than 25% from baseline levels.
[0646] 555. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of angiopoietin by more than 50% from the baseline level.
[0647] 556. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of angiopoietin by more than 100% from the baseline level.
[0648] 557. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of PDGF-BB by more than 25% from the baseline level.
[0649] 558. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of PDGF-BB by more than 50% from the baseline level.
[0650] 559. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of PDGF-BB by more than 100% from the baseline level.
[0651] 560. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase HGF production by more than 25% from baseline levels.
[0652] 561. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase HGF production by more than 50% from baseline levels.
[0653] 562. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase HGF production by more than 100% from baseline levels.
[0654] 563. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of soluble HLA-G by more than 25% from the baseline level.
[0655] 564. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of soluble HLA-G by more than 50% from the baseline level.
[0656] 565. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of soluble HLA-G by more than 100% from the baseline level.
[0657] 566. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of NRF2 by more than 25% from the baseline level.
[0658] 567. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of NRF2 by more than 50% from the baseline level.
[0659] 568. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of NRF2 by more than 100% from the baseline level.
[0660] 569. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of HO-1 by more than 25% from the baseline level.
[0661] 570. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of HO-1 by more than 50% from the baseline level.
[0662] 571. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of HO-1 by more than 100% from the baseline level.
[0663] 572. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of bcl-2 by more than 25% from the baseline level.
[0664] 573. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of bcl-2 by more than 50% from the baseline level.
[0665] 574. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of bcl-2 by more than 100% from the baseline level.
[0666] 575. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of bcl-2xL by more than 25% from the baseline level.
[0667] 576. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of bcl-2xL by more than 50% from the baseline level.
[0668] 577. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of bcl-2xL by more than 100% from the baseline level.
[0669] 578. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase livin production by more than 25% from baseline levels.
[0670] 579. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase livin production by more than 50% from baseline levels.
[0671] 580. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase livin production by more than 100% from baseline levels.
[0672] 581. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase survivin production by more than 25% from baseline levels.
[0673] 582. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase survivin production by more than 50% from baseline levels.
[0674] 583. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase survivin production by more than 100% from baseline levels.
[0675] 584. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of c-met by more than 25% from the baseline level.
[0676] 585. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of c-met by more than 50% from the baseline level.
[0677] 586. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of c-met by more than 100% from the baseline level.
[0678] 587. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of AI-1 by more than 25% from the baseline level.
[0679] 588. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of AI-1 by more than 50% from the baseline level.
[0680] 589. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of AI-1 by more than 100% from the baseline level.
[0681] 590. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of TAP-1 by more than 25% from the baseline level.
[0682] 591. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of TAP-1 by more than 50% from the baseline level.
[0683] 592. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of TAP-1 by more than 100% from the baseline level.
[0684] 593. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of IL-10 receptors by more than 25% from baseline levels.
[0685] 594. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of IL-10 receptors by more than 50% from baseline levels.
[0686] 595. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of IL-10 receptors by more than 100% from baseline levels.
[0687] 596. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of arginase by more than 25% from the baseline level.
[0688] 597. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of arginase by more than 50% from the baseline level.
[0689] 598. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of arginase by more than 100% from the baseline level.
[0690] 599. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of indoleamine 2,3-dioxygenase by more than 25% from the baseline level.
[0691] 600. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of indoleamine 2,3-dioxygenase by more than 50% from the baseline level.
[0692] 601. The method of aspect 511, wherein the hypoxia is applied for a time and intensity sufficient to increase the production of indoleamine 2,3-dioxygenase by more than 100% from the baseline level.
[0693] 602. The method of aspect 510, wherein the immortalized gene is a large T antigen.
[0694] 603. The method of aspect 510, wherein the immortalization gene is PIM1.
[0695] 604. The method of aspect 510, wherein the immortalization gene is Ras.
[0696] 605. The method of aspect 510, wherein the immortalization gene is Raf.
[0697] 606. The method of aspect 510, wherein the immortalization gene is abl.
[0698] 607. The method of aspect 510, wherein the immortal gene is bcr-abl.
[0699] 608. The method of aspect 510, wherein the immortalization gene is vav.
[0700] 609. The method of aspect 510, wherein the immortalization gene is erb.
[0701] 610. The method of aspect 510, wherein the immortal gene is her2.
[0702] 611. The method of aspect 510, wherein the immortalization gene is c-kit.
[0703] 612. The method of aspect 510, wherein the immortalization gene is transferred to the target cell by means of fusion with tumor-transformed cells.
[0704] 613. The method of aspect 510, wherein the immortal gene is activated in a temperature-dependent manner.
[0705] 614. The method of aspect 56, wherein the pluripotent stem cells are generated from partially undifferentiated stem cells.
[0706] 615. The method of aspect 614, wherein the portion of undifferentiated stem cells is mesenchymal stem cells.
[0707] 616. The method of aspect 615, wherein the partially undifferentiated stem cells are generated by dedifferentiating monocytes or mononuclear cells.
[0708] 617. The method of aspect 616, wherein the monocyte expresses c-kit.
[0709] 618. The method of aspect 616, wherein the monocyte expresses CD16.
[0710] 619. The method of aspect 616, wherein the monocyte expresses CD14.
[0711] 620. The method of aspect 616, wherein the monocyte expresses arginase.
[0712] 621. The method of aspect 616, wherein the monocyte expresses CD246.
[0713] 622. The method of aspect 616, wherein the monocytes are treated with a histone deacetylase inhibitor.
[0714] 623. The method of aspect 622, wherein the monocytes are transfected with a dedifferentiation agent.
[0715] 624. The method of aspect 623, wherein the dedifferentiating agent is KLF4.
[0716] 625. The method of aspect 623, wherein the dedifferentiating agent is c-myc.
[0717] 626. The method of aspect 623, wherein the dedifferentiator is KLF-4, c-myc, and TGF-β receptor.
[0718] 627. The method of aspect 623, wherein the dedifferentiator is an IL-3 receptor.
[0719] 628. The method of aspect 623, wherein the dedifferentiator is an IL-3 receptor and a KLR-4.
[0720] 629. The method of aspect 623, wherein the dedifferentiator is an IL-3 receptor, KLR-4, and c-myc.
[0721] 630. The method of aspect 623, wherein the dedifferentiator is an IL-3 receptor, KLR-4, c-myc, or TGF-β receptor.
[0722] 631. The method of aspect 623, wherein the dedifferentiating agent is hTERT.
[0723] 632. The method of aspect 623, wherein the dedifferentiating agent is OCT4.
[0724] 633. The method of aspect 623, wherein the dedifferentiating agent is NANOG.
[0725] 634. The method of aspect 623, wherein the dedifferentiating agent is NANOG and OCT4.
[0726] 635. The method of aspect 623, wherein the dedifferentiation agent is derived from the cytoplasm of pluripotent stem cells.
[0727] 636. The method of aspect 623, wherein the dedifferentiation agent is an exosome derived from pluripotent stem cells.
[0728] 637. The method of aspect 623, wherein the dedifferentiating agent is a miRNA derived from pluripotent stem cells.
[0729] 638. The method of aspects 635 to 637, wherein the pluripotent stem cell is an iPSC cell.
[0730] 639. The method of aspects 635 to 637, wherein the pluripotent stem cells are stem cells of parthenogenesis origin.
[0731] 640. The method of aspects 635 to 637, wherein the pluripotent stem cells are stem cells derived from somatic cell nuclear transfer.
[0732] 641. The method of aspects 635 to 637, wherein the pluripotent stem cell is an iPSC cell.
[0733] 642. The method of aspect 622, wherein the histone deacetylase inhibitor is valproic acid.
[0734] 643. The method of aspect 642, wherein the valproic acid is administered at a concentration sufficient to induce an increase in OCT4 expression of more than 25%.
[0735] 644. The method of aspect 642, wherein the valproic acid is administered at a concentration sufficient to induce an increase in OCT4 expression of more than 50%.
[0736] 645. The method of aspect 642, wherein the valproic acid is administered at a concentration sufficient to induce an increase in OCT4 expression of more than 100%.
[0737] 646. The method of aspect 642, wherein the valproic acid is applied at a concentration sufficient to induce an increase in c-kit expression of more than 25%.
[0738] 647. The method of aspect 642, wherein the valproic acid is applied at a concentration sufficient to induce an increase in c-kit expression of more than 50%.
[0739] 648. The method of aspect 642, wherein the valproic acid is applied at a concentration sufficient to induce an increase in c-kit expression of more than 100%.
[0740] 649. The method of aspect 642, wherein the valproic acid is administered at a concentration sufficient to induce an increase in c-met expression of more than 25%.
[0741] 650. The method of aspect 642, wherein the valproic acid is administered at a concentration sufficient to induce an increase in c-met expression of more than 50%.
[0742] 651. The method of aspect 642, wherein the valproic acid is administered at a concentration sufficient to induce an increase in c-met expression of more than 100%.
[0743] 652. The method of aspect 642, wherein the valproic acid is applied at a concentration sufficient to induce an increase in c-mpl expression of more than 25%.
[0744] 653. The method of aspect 642, wherein the valproic acid is applied at a concentration sufficient to induce an increase in c-mpl expression of more than 50%.
[0745] 654. The method of aspect 642, wherein the valproic acid is applied at a concentration sufficient to induce an increase in c-mpl expression of more than 100%.
[0746] 655. The method of aspect 622, wherein the histone deacetylase inhibitor is trichosuccinimide A.
[0747] 656. The method of aspect 655, wherein the trichosmin A is applied at a concentration sufficient to induce an increase in OCT4 expression of more than 25%.
[0748] 657. The method of aspect 655, wherein the trichosmin A is applied at a concentration sufficient to induce an increase in OCT4 expression of more than 50%.
[0749] 658. The method of aspect 655, wherein the trichosmin A is applied at a concentration sufficient to induce an increase in OCT4 expression of more than 100%.
[0750] 659. The method of aspect 655, wherein the trichosmin A is applied at a concentration sufficient to induce an increase in c-kit expression of more than 25%.
[0751] 660. The method of aspect 655, wherein the trichosmin A is applied at a concentration sufficient to induce an increase in c-kit expression of more than 50%.
[0752] 661. The method of aspect 655, wherein the trichosmin A is applied at a concentration sufficient to induce an increase in c-kit expression of more than 100%.
[0753] 662. The method of aspect 655, wherein the trichosmin A is applied at a concentration sufficient to induce an increase in c-met expression of more than 25%.
[0754] 663. The method of aspect 655, wherein the trichosmin A is applied at a concentration sufficient to induce an increase in c-met expression of more than 50%.
[0755] 664. The method of aspect 655, wherein the trichosmin A is applied at a concentration sufficient to induce an increase in c-met expression of more than 100%.
[0756] 665. The method of aspect 655, wherein the trichosmin A is applied at a concentration sufficient to induce an increase in c-mpl expression of more than 25%.
[0757] 666. The method of aspect 655, wherein the trichosmin A is applied at a concentration sufficient to induce an increase in c-mpl expression of more than 50%.
[0758] 667. The method of aspect 655, wherein the trichosmin A is applied at a concentration sufficient to induce an increase in c-mpl expression of more than 100%.
[0759] 668. The method of aspect 622, wherein the histone deacetylase inhibitor is sulforaphane.
[0760] 669. The method of aspect 668, wherein the sulforaphane is applied at a concentration sufficient to induce an increase in OCT4 expression of more than 25%.
[0761] 670. The method of aspect 668, wherein the sulforaphane is applied at a concentration sufficient to induce an increase in OCT4 expression of more than 50%.
[0762] 671. The method of aspect 668, wherein the sulforaphane is applied at a concentration sufficient to induce an increase in OCT4 expression of more than 100%.
[0763] 672. The method of aspect 668, wherein the sulforaphane is applied at a concentration sufficient to induce an increase in c-kit expression of more than 25%.
[0764] 673. The method of aspect 668, wherein the sulforaphane is applied at a concentration sufficient to induce an increase in c-kit expression of more than 50%.
[0765] 674. The method of aspect 668, wherein the sulforaphane is applied at a concentration sufficient to induce an increase in c-kit expression of more than 100%.
[0766] 675. The method of aspect 668, wherein the sulforaphane is applied at a concentration sufficient to induce an increase in c-met expression of more than 25%.
[0767] 676. The method of aspect 668, wherein the sulforaphane is applied at a concentration sufficient to induce an increase in c-met expression of more than 50%.
[0768] 677. The method of aspect 668, wherein the sulforaphane is applied at a concentration sufficient to induce an increase in c-met expression of more than 100%.
[0769] 678. The method of aspect 668, wherein the sulforaphane is applied at a concentration sufficient to induce an increase in c-mpl expression of more than 25%.
[0770] 679. The method of aspect 668, wherein the sulforaphane is applied at a concentration sufficient to induce an increase in c-mpl expression of more than 50%.
[0771] 680. The method of aspect 668, wherein the sulforaphane is applied at a concentration sufficient to induce an increase in c-mpl expression of more than 100%.
[0772] 681. The method of aspect 622, wherein the histone deacetylase inhibitor is phenyl butyrate.
[0773] 682. The method of aspect 668, wherein the phenyl butyrate is administered at a concentration sufficient to induce an increase in OCT4 expression of more than 25%.
[0774] 683. The method of aspect 668, wherein the phenyl butyrate is administered at a concentration sufficient to induce an increase in OCT4 expression of more than 50%.
[0775] 684. The method of aspect 668, wherein the phenyl butyrate is administered at a concentration sufficient to induce an increase in OCT4 expression of more than 100%.
[0776] 685. The method of aspect 668, wherein the phenyl butyrate is applied at a concentration sufficient to induce an increase in c-kit expression of more than 25%.
[0777] 686. The method of aspect 668, wherein the phenyl butyrate is applied at a concentration sufficient to induce an increase in c-kit expression of more than 50%.
[0778] 687. The method of aspect 668, wherein the phenyl butyrate is applied at a concentration sufficient to induce an increase in c-kit expression of more than 100%.
[0779] 688. The method of aspect 668, wherein the phenyl butyrate is applied at a concentration sufficient to induce an increase in c-met expression of more than 25%.
[0780] 689. The method of aspect 668, wherein the phenyl butyrate is applied at a concentration sufficient to induce an increase in c-met expression of more than 50%.
[0781] 690. The method of aspect 668, wherein the phenyl butyrate is applied at a concentration sufficient to induce an increase in c-met expression of more than 100%.
[0782] 691. The method of aspect 668, wherein the phenyl butyrate is applied at a concentration sufficient to induce an increase in c-mpl expression of more than 25%.
[0783] 692. The method of aspect 668, wherein the phenyl butyrate is applied at a concentration sufficient to induce an increase in c-mpl expression of more than 50%.
[0784] 693. The method of aspect 668, wherein the phenyl butyrate is applied at a concentration sufficient to induce an increase in c-mpl expression of more than 100%.
[0785] 694. The method of aspect 622, wherein the histone deacetylase inhibitor is entinolide.
[0786] 695. The method of aspect 681, wherein the entenostatin is administered at a concentration sufficient to induce an increase in OCT4 expression of more than 25%.
[0787] 696. The method of aspect 681, wherein the entenostatin is administered at a concentration sufficient to induce an increase in OCT4 expression of more than 50%.
[0788] 697. The method of aspect 681, wherein the entenostatin is administered at a concentration sufficient to induce an increase in OCT4 expression of more than 100%.
[0789] 698. The method of aspect 681, wherein the entenostatin is administered at a concentration sufficient to induce an increase in c-kit expression of more than 25%.
[0790] 699. The method of aspect 681, wherein the entenostatin is administered at a concentration sufficient to induce an increase in c-kit expression of more than 50%.
[0791] 700. The method of aspect 681, wherein the entenostatin is administered at a concentration sufficient to induce an increase in c-kit expression of more than 100%.
[0792] 701. The method of aspect 681, wherein the entenostatin is administered at a concentration sufficient to induce an increase in c-met expression of more than 25%.
[0793] 702. The method of aspect 681, wherein the entenostatin is administered at a concentration sufficient to induce an increase in c-met expression of more than 50%.
[0794] 703. The method of aspect 681, wherein the entenostatin is administered at a concentration sufficient to induce an increase in c-met expression of more than 100%.
[0795] 704. The method of aspect 681, wherein the entenostatin is administered at a concentration sufficient to induce an increase in c-mpl expression of more than 25%.
[0796] 705. The method of aspect 681, wherein the entenostatin is administered at a concentration sufficient to induce an increase in c-mpl expression of more than 50%.
[0797] 706. The method of aspect 681, wherein the entenostatin is administered at a concentration sufficient to induce an increase in c-mpl expression of more than 100%.
[0798] 707. The method of aspect 622, wherein the histone deacetylase inhibitor is vorinostat.
[0799] 708. The method of aspect 707, wherein vorinostat is administered at a concentration sufficient to induce an increase in OCT4 expression of more than 25%.
[0800] 709. The method of aspect 707, wherein vorinostat is administered at a concentration sufficient to induce an increase in OCT4 expression of more than 50%.
[0801] 710. The method of aspect 707, wherein vorinostat is administered at a concentration sufficient to induce an increase in OCT4 expression of more than 100%.
[0802] 711. The method of aspect 707, wherein vorinostat is administered at a concentration sufficient to induce an increase in c-kit expression of more than 25%.
[0803] 712. The method of aspect 707, wherein vorinostat is administered at a concentration sufficient to induce an increase in c-kit expression of more than 50%.
[0804] 713. The method of aspect 707, wherein vorinostat is administered at a concentration sufficient to induce an increase in c-kit expression of more than 100%.
[0805] 714. The method of aspect 707, wherein vorinostat is administered at a concentration sufficient to induce an increase in c-met expression of more than 25%.
[0806] 715. The method of aspect 707, wherein vorinostat is administered at a concentration sufficient to induce an increase in c-met expression of more than 50%.
[0807] 716. The method of aspect 707, wherein vorinostat is administered at a concentration sufficient to induce an increase in c-met expression of more than 100%.
[0808] 717. The method of aspect 707, wherein vorinostat is administered at a concentration sufficient to induce an increase in c-mpl expression of more than 25%.
[0809] 718. The method of aspect 707, wherein vorinostat is administered at a concentration sufficient to induce an increase in c-mpl expression of more than 50%.
[0810] 719. The method of aspect 707, wherein vorinostat is administered at a concentration sufficient to induce an increase in c-mpl expression of more than 100%.
[0811] 720. The method of aspect 615, wherein the mesenchymal stem cells express CD73.
[0812] 721. The method of aspect 615, wherein the mesenchymal stem cells express CD105.
[0813] 722. The method of aspect 615, wherein the mesenchymal stem cells express c-kit.
[0814] 723. The method of aspect 615, wherein the mesenchymal stem cells express DAZZLE.
[0815] 724. The method of aspect 615, wherein the mesenchymal stem cells express HGF receptors.
[0816] 725. The method of aspect 616, wherein the mesenchymal stem cells express CD56.
[0817] 726. The method of aspect 616, wherein the mesenchymal stem cells express the LIF receptor.
[0818] 727. The method of aspect 616, wherein the mesenchymal stem cells express CD90.
[0819] 728. The method of aspect 616, wherein the mesenchymal stem cells express PD-L1.
[0820] 729. The method of aspect 616, wherein the mesenchymal stem cells express activin receptors.
[0821] 730. The method of aspect 616, wherein the mesenchymal stem cells express endothelial receptor.
[0822] 731. The method of aspect 616, wherein the mesenchymal stem cells express the FGF-1 receptor.
[0823] 732. The method of aspect 616, wherein the mesenchymal stem cells express interferon-γ receptors.
[0824] 733. The method of aspect 616, wherein the mesenchymal stem cells express TNF-α receptor p55.
[0825] 734. The method of aspect 616, wherein the mesenchymal stem cells express TNF-α receptor p75.
[0826] 735. The method of aspect 616, wherein the mesenchymal stem cells express NGF receptors.
[0827] 736. The method of aspect 616, wherein the mesenchymal stem cells express hCG receptors.
[0828] 737. The method of aspect 616, wherein the mesenchymal stem cells express progesterone receptors.
[0829] 738. The method of aspect 616, wherein the mesenchymal stem cells express testosterone receptors.
[0830] 739. The method of aspect 616, wherein the mesenchymal stem cells express the Klotho receptor.
[0831] 740. The method of aspect 616, wherein the mesenchymal stem cells express interleukin-1β receptors.
[0832] 741. The method of aspect 616, wherein the mesenchymal stem cells express interleukin-7 receptors.
[0833] 742. The method of aspect 616, wherein the mesenchymal stem cells express interleukin-12 receptors.
[0834] 743. The method of aspect 616, wherein the mesenchymal stem cells express the EGF receptor.
[0835] 744. The method of aspect 616, wherein the mesenchymal stem cells express angiopoietin receptors.
[0836] 745. The method of aspect 616, wherein the mesenchymal stem cells express G-CSF receptors.
[0837] 746. The method of aspect 616, wherein the mesenchymal stem cells express the M-CSF receptor.
[0838] 747. The method of aspect 616, wherein the mesenchymal stem cells express the GM-CSF receptor.
[0839] 748. The method of aspect 616, wherein the mesenchymal stem cells express the TGF-β receptor.
[0840] 749. The method of aspect 616, wherein the mesenchymal stem cells express endothelial receptor.
[0841] 750. The method of aspect 616, wherein the mesenchymal stem cells express calcitonin receptors.
[0842] 751. The method of aspect 506, wherein the heart-specific progenitor cells express α-actin.
[0843] 752. The method of aspect 506, wherein the heart-specific progenitor cells express troponin.
[0844] 753. The method of aspect 506, wherein the heart-specific progenitor cells express myosin.
[0845] 754. The method of aspect 506, wherein the heart-specific progenitor cells express myosin heavy chain.
[0846] 755. The method of aspect 506, wherein the heart-specific progenitor cells express CD133.
[0847] 756. The method of aspect 506, wherein the heart-specific progenitor cells express myosin heavy chain and CD133.
[0848] 757. The method of aspect 506, wherein the heart-specific progenitor cells express MLC2v.
[0849] 758. The method of aspect 506, wherein the heart-specific progenitor cells express My20.
[0850] 759. The method of aspect 506, wherein the heart-specific progenitor cells express cMHC and NKX2-5.
[0851] 760. The method of aspect 506, wherein the heart-specific progenitor cells express MEF2c.
[0852] 761. The method of aspect 506, wherein the heart-specific progenitor cells express STAT4.
[0853] 762. The method of aspect 506, wherein the heart-specific progenitor cells express STAT6.
[0854] 763. The method of aspect 506, wherein the heart-specific progenitor cells express My20 and CD133.
[0855] 764. The method of aspect 506, wherein the heart-specific progenitor cells express My20 and CD34.
[0856] 765. The method of aspect 506, wherein the heart-specific progenitor cells express My20 and c-met.
[0857] 766. The method of aspect 506, wherein the heart-specific progenitor cells express My20 and c-kit.
[0858] 767. The method of aspect 506, wherein the heart-specific progenitor cells express GATA4.
[0859] 768. The method of aspect 506, wherein the heart-specific progenitor cells express ISLL and cTNI.
[0860] 769. The method of aspect 506, wherein the heart-specific progenitor cells express ISLL and cTNI.
[0861] 770. The method of aspect 506, wherein the heart-specific progenitor cells express MLC2a.
[0862] 771. The method of aspect 506, wherein the heart-specific progenitor cells express myosin heavy chain and CD133.
[0863] 772. The method of aspect 506, wherein the heart-specific progenitor cells express myosin heavy chain and CD34.
[0864] 773. The method of aspect 506, wherein the heart-specific progenitor cells express myosin heavy chain and c-met.
[0865] 774. The method of aspect 506, wherein the heart-specific progenitor cells express cMHC, NKX2-5 and c-kit.
[0866] 775. The method of aspect 506, wherein the heart-specific progenitor cells express cMHC, NKX2-5 and CD133.
[0867] 776. The method of aspect 506, wherein the heart-specific progenitor cells express cMHC, NKX2-5 and CD34.
[0868] 777. The method of aspect 506, wherein the heart-specific progenitor cells express cMHC, NKX2-5 and c-met.
[0869] 778. The method of aspect 506, wherein the heart-specific progenitor cells express MEF2c and c-kit.
[0870] 779. The method of aspect 506, wherein the heart-specific progenitor cells express MEF2c and CD133.
[0871] 780. The method of aspect 506, wherein the heart-specific progenitor cells express MEF2c and CD34.
[0872] 781. The method of aspect 506, wherein the heart-specific progenitor cells express MEF2c and c-met.
[0873] 782. The method of aspect 506, wherein the heart-specific progenitor cells express MLC2a and c-kit.
[0874] 783. The method of aspect 506, wherein the heart-specific progenitor cells express MLC2a and CD133.
[0875] 784. The method of aspect 506, wherein the heart-specific progenitor cells express MLC2a and CD34.
[0876] 785. The method of aspect 506, wherein the heart-specific progenitor cells express MLC2a and c-met.
[0877] 786. The method of aspect 506, wherein the differentiation of the pluripotent stem cells.
[0878] 786. The method of aspect 506, wherein the pluripotent stem cells are treated with a WNT agonist.
[0879] 787. The method of aspect 786, wherein the WNT agonist is 1-azacamparone (9-bromo-7,12-dihydro-pyrido[3′,2′:2,3]azacyclobutano[4,5-b]indole-6(5H)-one) or BIO ((2′Z,3′E)-6-bromoindorubin-3′-oxime).
[0880] 788. The method of aspect 786, wherein the WNT agonist is CHIR99021 (6-(2-(4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-ylamino)ethylamino)nicotinonitrile).
[0881] 789. The method of aspect 786, wherein the WNT agonist is AR-A014418 (N-(4-methoxybenzyl)-N′-(5-nitro-1,3-thiazolyl-2-yl)urea).
[0882] 790. The method of aspect 786, wherein the WNT agonist is indirubin-3'-monoxime.
[0883] 791. The method of aspect 786, wherein the WNT agonist is 5-iodo-indirubin-3'-monoxime.
[0884] 792. The method of aspect 786, wherein the WNT agonist is camparone (9-bromo-7,12-dihydroindole-[3,2-d][1]benzozazepine-6(5H)-one).
[0885] 793. The method of aspect 786, wherein the WNT agonist is SB-415286 (3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitro-phenyl)-1H-pyrrole-2,5-dione).
[0886] 793. The method of aspect 786, wherein the WNT agonist is SB-216763 (3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione).
[0887] 794. The method of aspect 786, wherein the WNT agonist is Maybridge SEW00923SC (2-aniline-5-phenyl-1,3,4-oxadiazole).
[0888] 795. The method of aspect 786, wherein the WNT agonist is (Z)-5-(2,3-methylenedioxyphenyl)imidazolinidine-2,4-dione.
[0889] 796. The method of aspect 786, wherein the WNT agonist is TWS119 (3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol).
[0890] 797. The method of aspect 786, wherein the WNT agonist is CHIR98014 (N2-(2-(4-(2,4-dichlorophenyl)-5-(1H-imidazol-1-yl)pyrimidin-2-ylamino)ethyl)-5-nitropyridine-2,6-diamine).
[0891] 798. The method of aspect 786, wherein the WNT agonist is SB415286 (3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione).
[0892] 799. The method of aspect 786, wherein the WNT agonist is Tideglusib (also known as NP031112 or NP-12; 1,2,4-thiadiazolidine-3,5-dione, 2-(1-naphthyl)-4-(phenylmethyl)).
[0893] 800. The method of aspect 786, wherein the WNT agonist is LY2090314 (1H-pyrrolo-2,5-dione, 3-imidazol[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepine-7-yl]).
[0894] 801. The method of aspect 506, wherein the pluripotent stem cells are treated with a GSK-3 inhibitor.
[0895] 802. The method of aspect 801, wherein the GSK-3 inhibitor is lithium.
[0896] 803. The method of aspect 801, wherein the GSK-3 inhibitor is Paris saponin VII.
[0897] 804. The method of aspect 801, wherein the GSK-3 inhibitor is MAZ51.
[0898] 805. The method of aspect 801, wherein the GSK-3 inhibitor is BRD0705.
[0899] 806. The method of aspect 801, wherein the GSK-3 inhibitor is Elraglusib (9-ING-41).
[0900] 807. The method of aspect 801, wherein the GSK-3 inhibitor is CP21.
[0901] 808. The method of aspect 801, wherein the GSK-3 inhibitor is BIO-acetone oxime.
[0902] 809. The method of aspect 801, wherein the GSK-3 inhibitor is bikinin.
[0903] 810. The method of aspect 801, wherein the GSK-3 inhibitor is IM12.
[0904] 811. The method of aspect 801, wherein the GSK-3 inhibitor is AR-A014418.
[0905] 812. The method of aspect 802, wherein the lithium is applied together with valproic acid.
[0906] 813. The method of aspect 802, wherein the lithium is applied together with phenyl butyrate.
[0907] 814. The method of aspect 802, wherein the lithium is applied together with trichosmin A.
[0908] 815. The method of aspect 802, wherein the lithium is applied together with sulforaphane.
[0909] 816. The method of aspect 802, wherein the lithium is administered together with belistat.
[0910] 817. The method of aspect 802, wherein the lithium is administered together with givinostine.
[0911] 818. The method of aspect 802, wherein the lithium is administered together with interleukin-3.
[0912] 819. The method of aspect 802, wherein the lithium is administered together with interleukin-7.
[0913] 820. The method of aspect 802, wherein the lithium is administered together with interleukin-11.
[0914] 821. The method of aspect 803, wherein the Paris saponin VII is applied together with valproic acid.
[0915] 822. The method of aspect 803, wherein the Paris saponin VII is applied together with phenyl butyrate.
[0916] 823. The method of aspect 803, wherein the Paris saponin VII is applied together with qugulisudin A.
[0917] 824. The method of aspect 803, wherein the Paris saponin VII is applied together with sulforaphane.
[0918] 825. The method of aspect 803, wherein the Paris saponin VII is administered together with belistat.
[0919] 826. The method of aspect 803, wherein the Paris saponin VII is administered together with gemvinosat.
[0920] 827. The method of aspect 803, wherein the Paris saponin VII is administered together with interleukin-3.
[0921] 828. The method of aspect 803, wherein the Paris saponin VII is administered together with interleukin-7.
[0922] 829. The method of aspect 803, wherein the Paris saponin VII is administered together with interleukin-11.
[0923] 830. The method of aspect 804, wherein the MAZ51 is applied together with valproic acid.
[0924] 831. The method of aspect 804, wherein the MAZ51 is applied together with phenyl butyrate.
[0925] 832. The method of aspect 804, wherein the MAZ51 is administered together with qugulijunin A.
[0926] 833. The method of aspect 804, wherein the MAZ51 is applied together with sulforaphane.
[0927] 834. The method of aspect 804, wherein the MAZ51 is administered together with belistat.
[0928] 835. The method of aspect 804, wherein the MAZ51 is administered together with givinostine.
[0929] 836. The method of aspect 804, wherein the MAZ51 is administered together with interleukin-3.
[0930] 837. The method of aspect 804, wherein the MAZ51 is administered together with interleukin-7.
[0931] 838. The method of aspect 804, wherein the MAZ51 is administered together with interleukin-11.
[0932] 839. The method of aspect 805, wherein the BRD0705 is applied together with valproic acid.
[0933] 840. The method of aspect 805, wherein the BRD0705 is applied together with phenyl butyrate.
[0934] 841. The method of aspect 805, wherein BRD0705 is administered together with qugulisuin A.
[0935] 842. The method of aspect 805, wherein BRD0705 is applied together with sulforaphane.
[0936] 843. The method of aspect 805, wherein the BRD0705 is administered together with belistat.
[0937] 844. The method of aspect 805, wherein the BRD0705 is administered together with givinostine.
[0938] 845. The method of aspect 805, wherein the BRD0705 is administered together with interleukin-3.
[0939] 846. The method of aspect 805, wherein the BRD0705 is administered together with interleukin-7.
[0940] 847. The method of aspect 805, wherein the BRD0705 is administered together with interleukin-11.
[0941] 848. The method of aspect 806, wherein Elraglusib is administered together with valproic acid.
[0942] 849. The method of aspect 806, wherein the Elraglusib is administered together with phenyl butyrate.
[0943] 850. The method of aspect 806, wherein Elraglusib is administered together with trigonellin A.
[0944] 851. The method of aspect 806, wherein Elraglusib is applied together with sulforaphane.
[0945] 852. The method of aspect 806, wherein the Elraglusib is administered together with belistat.
[0946] 853. The method of aspect 806, wherein Elraglusib is administered together with givinostine.
[0947] 854. The method of aspect 806, wherein the Elraglusib is administered together with interleukin-3.
[0948] 855. The method of aspect 806, wherein the Elraglusib is administered together with interleukin-7.
[0949] 856. The method of aspect 806, wherein the Elraglusib is administered together with interleukin-11.
[0950] 857. The method of aspect 807, wherein the CP21 is applied together with valproic acid.
[0951] 858. The method of aspect 807, wherein CP21 is applied together with phenyl butyrate.
[0952] 859. The method of aspect 807, wherein CP21 is administered together with qugulijunin A.
[0953] 860. The method of aspect 807, wherein CP21 is applied together with sulforaphane.
[0954] 861. The method of aspect 807, wherein the CP21 is administered together with belistat.
[0955] 862. The method of aspect 807, wherein the CP21 is administered together with gevinostat.
[0956] 863. The method of aspect 807, wherein CP21 is administered together with interleukin-3.
[0957] 864. The method of aspect 807, wherein the CP21 is administered together with interleukin-7.
[0958] 865. The method of aspect 807, wherein CP21 is administered together with interleukin-11.
[0959] 866. The method of aspect 808, wherein the BIO-acetone oxime is administered together with valproic acid.
[0960] 867. The method of aspect 808, wherein the BIO-acetone oxime is administered together with phenyl butyrate.
[0961] 868. The method of aspect 808, wherein the BIO-acetone oxime is administered together with trichosmin A.
[0962] 869. The method of aspect 808, wherein the BIO-acetone oxime is applied together with sulforaphane.
[0963] 870. The method of aspect 808, wherein the BIO-acetone oxime is administered together with belistat.
[0964] 871. The method of aspect 808, wherein the BIO-acetone oxime is administered together with gemvinostine.
[0965] 872. The method of aspect 808, wherein the BIO-acetone oxime is administered together with interleukin-3.
[0966] 873. The method of aspect 808, wherein the BIO-acetone oxime is administered together with interleukin-7.
[0967] 874. The method of aspect 808, wherein the BIO-acetone oxime is administered together with interleukin-11.
[0968] 875. The method of aspect 809, wherein the bikinin is administered together with valproic acid.
[0969] 876. The method of aspect 809, wherein the bikinin is administered together with phenyl butyrate.
[0970] 877. The method of aspect 809, wherein the bikinin is administered together with trichosmin A.
[0971] 878. The method of aspect 809, wherein the bikinin is applied together with sulforaphane.
[0972] 879. The method of aspect 809, wherein the bikinin is administered together with belistat.
[0973] 880. The method of aspect 809, wherein the bikinin is administered together with givinostine.
[0974] 881. The method of aspect 809, wherein the bikinin is administered together with interleukin-3.
[0975] 882. The method of aspect 809, wherein the bikinin is administered together with interleukin-7.
[0976] 883. The method of aspect 809, wherein the bikinin is administered together with interleukin-11.
[0977] 884. The method of aspect 810, wherein the IM12 is applied together with valproic acid.
[0978] 885. The method of aspect 810, wherein the IM12 is applied together with phenyl butyrate.
[0979] 886. The method of aspect 810, wherein the IM12 is administered together with qugulisulin A.
[0980] 887. The method of aspect 810, wherein the IM12 is applied together with sulforaphane.
[0981] 888. The method of aspect 810, wherein the IM12 is administered together with belistat.
[0982] 889. The method of aspect 810, wherein the IM12 is administered together with gevinostat.
[0983] 890. The method of aspect 810, wherein the IM12 is administered together with interleukin-3.
[0984] 891. The method of aspect 810, wherein the IM12 is administered together with interleukin-7.
[0985] 892. The method of aspect 810, wherein the IM12 is administered together with interleukin-11.
[0986] 893. The method of aspect 811, wherein the AR-A014418 is administered together with valproic acid.
[0987] 894. The method of aspect 811, wherein the AR-A014418 is applied together with phenyl butyrate.
[0988] 895. The method of aspect 811, wherein the AR-A014418 is administered together with qugulisulin A.
[0989] 896. The method of aspect 811, wherein the AR-A014418 is applied together with sulforaphane.
[0990] 897. The method of aspect 811, wherein the AR-A014418 is administered together with belistat.
[0991] 898. The method of aspect 811, wherein the AR-A014418 is administered together with givinostine.
[0992] 899. The method of aspect 811, wherein the AR-A014418 is administered together with interleukin-3.
[0993] 900. The method of aspect 811, wherein the AR-A014418 is administered together with interleukin-7.
[0994] 901. The method of aspect 811, wherein the AR-A014418 is administered together with interleukin-11.
[0995] 902. A method for generating progenitor cells of a desired tissue from pluripotent stem cells, comprising the steps of: a) identifying embryonic cytokines associated with the differentiation of the tissue; b) applying the cytokines to an embryoid body derived from the pluripotent stem cells; and c) isolating and expanding the progenitor cells.
[0996] 903. The method of aspect 902, wherein the embryo-related cytokines are detected by flow cytometry.
[0997] 904. The method of aspect 902, wherein the embryo-related cytokines are detected by mass flow cytometry.
[0998] 905. The method of aspect 902, wherein the embryo-related cytokines are detected by immunohistochemistry.
[0999] 906. The method of aspect 902, wherein the embryo-related cytokines are detected by two-photon microscopy.
[1000] 907. The method of aspect 902, wherein the embryo-related cytokines are detected by GC-MS / MS.
[1001] 908. The method of aspect 902, wherein the embryo-related cytokines are detected by laser capture microdissection technique.
[1002] 909. The method of aspect 902, wherein the embryo-related cytokines are detected by microarray technology.
[1003] 910. The method of aspect 902, wherein the embryo-related cytokines are detected by in situ hybridization.
[1004] 911. The method of aspect 902, wherein a differentiation inhibitor is administered to induce specific progenitor cells to expand under conditions where no significant differentiation occurs.
[1005] 912. The method of aspect 911, wherein the differentiation inhibitor is a growth factor.
[1006] 913. The method of aspect 912, wherein the growth factor is a hematopoietic growth factor.
[1007] 914. The method of aspect 913, wherein the hematopoietic growth factor is EPO.
[1008] 915. The method of aspect 913, wherein the hematopoietic growth factor is GDNF.
[1009] 916. The method of aspect 913, wherein the hematopoietic growth factor is G-CSF.
[1010] 917. The method of aspect 913, wherein the hematopoietic growth factor is GM-CSF.
[1011] 918. The method of aspect 913, wherein the hematopoietic growth factor is GDF-9.
[1012] 919. The method of aspect 913, wherein the hematopoietic growth factor is HGF.
[1013] 920. The method of aspect 913, wherein the hematopoietic growth factor is HDGF.
[1014] 921. The method of aspect 913, wherein the hematopoietic growth factor is IGF.
[1015] 922. The method of aspect 913, wherein the hematopoietic growth factor is a Fas ligand immobilized to the matrix.
[1016] 923. The method of aspect 913, wherein the hematopoietic growth factor is a migration-stimulating factor.
[1017] 924. The method of aspect 913, wherein the hematopoietic growth factor is GDF-9.
[1018] 925. The method of aspect 913, wherein the hematopoietic growth factor is HGF.
[1019] 926. The method of aspect 913, wherein the hematopoietic growth factor is GDNF-8.
[1020] 927. The method of aspect 913, wherein the hematopoietic growth factor is GDNF-11.
[1021] 928. The method of aspect 913, wherein the hematopoietic growth factor is GDNF-15.
[1022] 929. The method of aspect 913, wherein the hematopoietic growth factor is hyaluronic acid.
[1023] 930. The method of aspect 913, wherein the hematopoietic growth factor is hyaluronic acid mixed with lithium.
[1024] 931. The method of aspect 913, wherein the hematopoietic growth factor is hyaluronic acid mixed with valproic acid.
[1025] 932. The method of aspect 913, wherein the hematopoietic growth factor is hyaluronic acid mixed with phenyl butyrate.
[1026] 933. The method of aspect 913, wherein the hematopoietic growth factor is hyaluronic acid mixed with sulforaphane.
[1027] 934. The method of aspect 913, wherein the hematopoietic growth factor is hyaluronic acid mixed with trichosmin A.
[1028] 935. The method of aspect 913, wherein the hematopoietic growth factor is hyaluronic acid mixed with a mononuclear cell conditioned medium.
[1029] 936. The method of aspect 935, wherein the monocyte conditioned medium is obtained by exposing the monocytes to allogeneic T cells.
[1030] 937. The method of aspect 936, wherein the allogeneic T cells express CD3.
[1031] 938. The method of aspect 936, wherein the allogeneic T cells express CD4.
[1032] 939. The method of aspect 936, wherein the allogeneic T cells express CD8.
[1033] 940. The method of aspect 936, wherein the allogeneic T cells express granzyme B.
[1034] 941. The method of aspect 936, wherein the allogeneic T cells express perforin.
[1035] 942. The method of aspect 936, wherein the allogeneic T cells express TNF-α when CD3 and CD28 bind.
[1036] 943. The method of aspect 936, wherein the allogeneic T cells express interferon-α when CD3 and CD28 bind.
[1037] 944. The method of aspect 936, wherein the allogeneic T cells express lymphotoxin when CD3 and CD28 bind.
[1038] 945. The method of aspect 936, wherein the allogeneic T cells express interferon-γ when CD3 and CD28 bind.
[1039] 946. The method of aspect 936, wherein the allogeneic T cells express interleukin-1β when CD3 and CD28 bind.
[1040] 947. The method of aspect 936, wherein the allogeneic T cells express interleukin-17 when CD3 and CD28 bind.
[1041] 948. The method of aspect 936, wherein the allogeneic T cells express TRANCE when CD3 and CD28 bind.
[1042] 949. The method of aspect 936, wherein the allogeneic T cells express HLA II when CD3 and CD28 bind.
[1043] 950. The method of aspect 936, wherein the allogeneic T cells express transport-associated protein 1 when CD3 and CD28 bind.
[1044] 951. The method of aspect 936, wherein the allogeneic T cells express TNF-α when CD3 and CD28 bind.
[1045] 952. The method of aspect 913, wherein the hematopoietic growth factor is hyaluronic acid mixed with a mesenchymal stem cell conditioned medium.
[1046] 953. The method of aspect 952, wherein the mesenchymal conditioned medium is obtained by exposing monocytes to allogeneic T cells.
[1047] 954. The method of aspect 953, wherein the allogeneic T cells express CD3.
[1048] 955. The method of aspect 953, wherein the allogeneic T cells express CD4.
[1049] 956. The method of aspect 953, wherein the allogeneic T cells express CD8.
[1050] 957. The method of aspect 953, wherein the allogeneic T cells express granzyme B.
[1051] 958. The method of aspect 953, wherein the allogeneic T cells express perforin.
[1052] 959. The method of aspect 953, wherein the allogeneic T cells express TNF-α when CD3 and CD28 bind.
[1053] 960. The method of aspect 953, wherein the allogeneic T cells express interferon-α when CD3 and CD28 bind.
[1054] 961. The method of aspect 953, wherein the allogeneic T cells express lymphotoxin when CD3 and CD28 bind.
[1055] 962. The method of aspect 953, wherein the allogeneic T cells express interferon-γ when CD3 and CD28 bind.
[1056] 963. The method of aspect 953, wherein the allogeneic T cells express interleukin-1β when CD3 and CD28 bind.
[1057] 964. The method of aspect 953, wherein the allogeneic T cells express interleukin-17 when CD3 and CD28 bind.
[1058] 965. The method of aspect 953, wherein the allogeneic T cells express TRANCE when CD3 and CD28 bind.
[1059] 966. The method of aspect 953, wherein the mesenchymal stem cells are pretreated with an NF-κB activator.
[1060] 967. The method of aspect 966, wherein the NF-κB activator is a Toll-like receptor activator.
[1061] 968. The method of aspect 966, wherein the NF-κB activator is an MDA activator.
[1062] 969. The method of aspect 966, wherein the NF-κB activator is a RIG-1 activator.
[1063] 970. The method of aspect 966, wherein the NF-κB activator is a MAP kinase activator.
[1064] 971. The method of aspect 966, wherein the NF-κB activator is quercetin.
[1065] 972. The method of aspect 966, wherein the NF-κB activator is a DNA extracellular trap.
[1066] 973. The method of aspect 966, wherein the NF-κB activator is yeast polysaccharide.
[1067] 974. The method of aspect 966, wherein the NF-κB activator is HMGB1.
[1068] 975. The method of aspect 966, wherein the NF-κB activator is TNF-α.
[1069] 976. The method of aspect 966, wherein the NF-κB activator is a cross-linked antibody against TLR3.
[1070] 977. The method of aspect 966, wherein the NF-κB activator is a cross-linked antibody against TLR4.
[1071] 978. The method of aspect 966, wherein the NF-κB activator is a cross-linked antibody against TLR7.
[1072] 979. The method of aspect 966, wherein the NF-κB activator is a cross-linked antibody against TLR9.
[1073] 980. The method of aspect 966, wherein the NF-κB activator is imiquimod.
[1074] 981. The method of aspect 966, wherein the NF-κB activator is resiminod.
[1075] 982. The method of aspect 966, wherein the NF-κB activator is lipopolysaccharide.
[1076] 983. The method of aspect 966, wherein the NF-κB activator is β-glucan.
[1077] 984. The method of aspect 966, wherein the NF-κB activator is a CpG DNA motif.
[1078] 985. The method of aspect 966, wherein the NF-κB activator is double-stranded RNA.
[1079] 986. The method of aspect 966, wherein the NF-κB activator is circular DNA.
[1080] 987. The method of aspect 966, wherein the NF-κB activator is uric acid crystal.
[1081] 988. The method of aspect 966, wherein the NF-κB activator is a yeast cell wall extract.
[1082] 989. The method of aspect 966, wherein the NF-κB activator is immunoomax.
[1083] 990. The method of aspect 966, wherein the NF-κB activator is an activated neutrophil.
[1084] 991. The method of aspect 966, wherein the NF-κB activator is interleukin-6.
[1085] 992. The method of aspect 966, wherein the NF-κB activator is interleukin-8.
[1086] 993. The method of aspect 966, wherein the NF-κB activator is interleukin-11.
[1087] 994. The method of aspect 966, wherein the NF-κB activator is interleukin-12.
[1088] 995. The method of aspect 966, wherein the NF-κB activator is interleukin-15.
[1089] 996. The method of aspect 966, wherein the NF-κB activator is interleukin-17.
[1090] 997. The method of aspect 966, wherein the NF-κB activator is interleukin-18.
[1091] 998. The method of aspect 966, wherein the NF-κB activator is interleukin-23.
[1092] 999. The method of aspect 966, wherein the NF-κB activator is interleukin-27.
[1093] 1000. The method of aspect 966, wherein the NF-κB activator is interleukin-33.
[1094] 1001. The method of aspect 912, wherein the growth factor is selected from the group consisting of: AM, Ang, BMP, BDNF, EGF, FGF, or Wnt protein; interleukins; soluble receptors of IL-1α, IL-1β, IL-1F1, IL-1F2, IL-1F3, IL-1F4, IL-1F5, IL-1F6, IL-1F7, IL-1F8, IL-1F9, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12 35 kDa α subunit, IL-12 40 IL-13, IL-14, IL-15, IL-16, IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F isoform 1, IL-17F isoform 2, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23 p19 subunit, IL-23 p40 subunit, IL-24, IL-25, IL-26, IL-27B, IL-27-p28, IL-28A, IL-28B, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, IL-36α, IL-36β, IL-36γ; interferon (IFN); soluble receptor for IFN-α, IFN-β, IFN-γ, IFN-λ1, IFN-λ2, IFN-λ3, IFN-K, IFN-ε, IFN-κ, IFN-τ, IFN-δ, IFN-ζ, IFN-ω or IFN-v; insulin or proinsulin; insulin receptor; leptin (LEP). Attached Figure Description
[1095] Figure 1 The bar chart shows the results of α-myosin heavy chain expression in progenitor cells with or without conditioned medium, valproic acid, or conditioned medium + valproic acid.
[1096] Figure 2 The bar chart shows the results of c-kit expression in progenitor cells produced with or without conditioned medium, valproic acid, or conditioned medium + valproic acid.
[1097] Figure 3 The bar chart shows the results of CD133 expression in progenitor cells produced with or without conditioned medium, valproic acid, or conditioned medium + valproic acid. Detailed Implementation
[1098] This invention provides a method for generating tissue-specific progenitor cells from pluripotent stem cells. In one embodiment, the invention provides a method for differentiating pluripotent stem cells into tissue-specific cells by co-culturing the pluripotent stem cells with factors released by a tissue corresponding to the desired type of differentiated progenitor cells or a cell line representing that tissue. In one embodiment, the invention teaches the formation of a cell line, such as a cardiac cell line, after stressor treatment, and factors produced by said cell line are used to induce pluripotent stem cell differentiation. In other embodiments, the invention provides a method for administering specific growth factors capable of replicating their embryonic development into the desired tissue. In other embodiments, microvesicles, exosomes, microRNAs, and circular DNA are used.
[1099] As used herein, "cardiomyocyte" or cardiac myocyte is the muscle cell that makes up the cardiac muscle. Each cardiomyocyte contains myofibrils, long chains of sarcomeres (the contractile units of a muscle cell). Cardiomyocytes exhibit a striped structure similar to skeletal muscle cells, but unlike multinucleated skeletal muscle cells, they contain only one nucleus. Cardiomyocytes have a high mitochondrial density, which enables them to rapidly produce ATP, thus making them highly resistant to fatigue. Mature cardiomyocytes may express one or more of the following cardiac markers: α-actin, MLC2v, MY20, cMHC, NKX2-5, GATA4, cTNT, cTNI, MEF2c, MLC2a, or any combination thereof. In some embodiments, mature cardiomyocytes express NKX2-5, MEF2c, or a combination thereof. Cardiac progenitor cells express early cardiac progenitor markers such as GATA4, ISL1, or a combination thereof.
[1100] As used herein, the term "functional cardiomyocyte" refers to differentiated cardiomyocytes capable of sending or receiving electrical signals. In some embodiments, if cardiomyocytes exhibit action potentials and / or Ca2+, then... 2+ If transient electrophysiological characteristics are present, then the cardiomyocyte is considered a functional cardiomyocyte.
[1101] As used herein, "differentiated non-cardiac cells" refer to cells that cannot differentiate into all cell types of an adult organism (i.e., non-pluripotent cells), and whose cell lineage is other than the cardiac lineage (e.g., fibroblasts, endoderm cells, mesodermal cells, epithelial cells, neurons, connective tissue cells, lymphocytes, or other tissue type lineages). Differentiated cells include, but are not limited to, pluripotent cells, oligopotent cells, unipotent cells, progenitor cells, and terminally differentiated cells. In specific implementations, cells with lower potency than more pluripotent cells are considered "differentiated" cells.
[1102] As used herein, cells differentiated into mesodermal, ectodermal, or endoderm lineages refer to cells that are directed to differentiate into a specific mesodermal, ectodermal, or endoderm lineage, respectively. Examples of cells differentiating into a mesodermal lineage or producing specific mesodermal cells include, but are not limited to, adipocytes, chondrocytes, cardioblasts, skin cells, hematopoietic cells, angiocytes, myoblasts, renal cells, urogenital cells, osteoblasts, pericardial cells, or stromal cells. Examples of cells differentiating into an ectodermal lineage include, but are not limited to, epidermal cells, neurogenic cells, and glial-generating cells. Examples of cells differentiating into an endoderm lineage include, but are not limited to, pleurigenic cells and hepatocytes, cells that produce the intestinal lining, and cells that produce pancreatic cells and visceral cells.
[1103] As used herein, the term "cell culture medium" (also referred to herein as "culture medium" or "culture medium") means a cell culture medium containing the nutrients necessary to maintain cell viability and support cell proliferation. Cell culture media may appropriately combine any of the following components: salts, buffers, amino acids, glucose or other sugars, antibiotics, serum or serum substitutes, and other components (such as peptide growth factors). Those skilled in the art can obtain cell culture media commonly used for specific cell types.
[1104] Somatic cells are the cells that make up the body of an organism. Somatic cells include the cells that make up the organs, skin, blood, bones, and connective tissues of an organism, but do not include germ cells.
[1105] The cells may be derived from, for example, humans or non-human mammals. Exemplary non-human mammals include, but are not limited to, mice, rats, cats, dogs, rabbits, guinea pigs, hamsters, sheep, pigs, horses, cattle, and non-human primates. In some embodiments, the cells are derived from adult human or non-human mammals. In some embodiments, the cells are derived from neonatal humans, adult human, or non-human mammals.
[1106] As used in this article, the term "totipotency" refers to the ability of a cell to form all cell lineages of an organism. For example, in mammals, only the fertilized egg and the blastomeres at the first cleavage stage are totipotent.
[1107] As used in this article, the term "pluripotent" refers to the ability of a cell to form all lineages of the body or somatic cells (i.e., the embryonic body). For example, embryonic stem cells are a type of pluripotent stem cell capable of forming cells from each of the three germ layers (ectoderm, mesoderm, and endoderm).
[1108] As used in this article, the term "pluripotent" refers to the ability of an adult stem cell to form multiple cell types within the same lineage. For example, hematopoietic stem cells can form all cell types of the blood cell lineage, such as lymphocytes and myeloid cells.
[1109] As used in this article, the term "oligopotency" refers to the ability of adult stem cells to differentiate into only a few different cell types. For example, lymphoid stem cells or myeloid stem cells can form lymphoid and myeloid cells, respectively.
[1110] As used in this article, the term "monopoietic" refers to the ability of a cell to form a single cell type. For example, spermatogonial stem cells can only form sperm cells.
[1111] As used in this article, the terms “direct reprogramming” or “transdifferentiation” refer to the generation of specific lineage cells (such as heart cells) from different types of cells (such as fibroblasts) without going through the intermediate step of dedifferentiating the cells into cells with pluripotent stem cell characteristics.
[1112] As used herein, the terms “subject” or “patient” refer to any animal, such as a domesticated animal, a zoo animal, or a human. A “subject” or “patient” can be a mammal, such as a dog, cat, bird, livestock, or human. Specific examples of “subject” and “patient” include, but are not limited to, individuals suffering from a heart disease or condition, and individuals exhibiting characteristics or symptoms associated with cardiac disease.
[1113] In one embodiment of the present invention, pluripotent stem cells are differentiated into progenitor cells of various tissues using a variety of tissue-specific differentiation methods based on differentiation-related embryological expression factors. Depending on the tissue, various factors can be applied. These factors include: bone morphogenetic protein (BMP)-1, bone morphogenetic protein-2, bone morphogenetic protein-3, bone morphogenetic protein-4, bone morphogenetic protein-5, bone morphogenetic protein-6, bone morphogenetic protein-7, bone morphogenetic protein-8, bone morphogenetic protein-9, bone morphogenetic protein-10, bone morphogenetic protein-11, bone morphogenetic protein-12, bone morphogenetic protein-13, bone morphogenetic protein-14, bone morphogenetic protein-15, brain-derived neurotrophic factor, ciliary neurotrophic factor, and cytokines. Induced neutrophil chemokine 1, cytokine-induced neutrophil chemokine 2α, cytokine-induced neutrophil chemokine 2β, β-endothelial growth factor, endothelin 1, epidermal growth factor, epithelial-derived neutrophil attractant, fibroblast growth factor (FGF) 4, fibroblast growth factor 5, fibroblast growth factor 6, fibroblast growth factor 7, fibroblast growth factor 8, fibroblast growth factor 8b, fibroblast growth factor 8c, fibroblast growth factor 9, fibroblast growth factor 10. Fibroblast growth factor (acidic), Fibroblast growth factor (basic), Growth-associated protein, Growth-associated protein α, Growth-associated protein β, Growth-associated protein γ, Heparin-bound epidermal growth factor, Hepatocyte growth factor, Insulin-like growth factor I, Insulin-like growth factor II, Insulin-like growth factor binding protein, Keratinocyte growth factor, Leukemia inhibitory factor, Neurotrophic factor-3, Neurotrophic factor-4, Placental growth factor, Placental growth factor 2, Platelet-derived endothelial growth factor, Platelet-derived growth factor, Blood Platelet-derived growth factor A chain, platelet-derived growth factor AA, platelet-derived growth factor AB, platelet-derived growth factor B chain, platelet-derived growth factor BB, pre-B cell growth stimulating factor, stem cell factor, transforming growth factor a, transforming growth factor β, transforming growth factor β1, transforming growth factor β1.2, transforming growth factor β2, transforming growth factor β3, latent transforming growth factor β1, transforming growth factor β-binding protein I, transforming growth factor β-binding protein II, transforming growth factor β-binding protein III, vascular endothelial growth factor.Exemplary cytokines may include, for example: interleukin (IL)-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, interferon (IFN), IFN-γ, tumor necrosis factor (TNF), TNF1, TNF2, TNF-α, macrophage colony-stimulating factor (M-CSF), granulocyte-monocyte colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), megakaryocyte colony-stimulating factor (Meg-CSF)-thrombopoietin, stem cell factors, and erythropoietin. Chemokines such as IP-10 and stromal cell-derived factor 1α may also be included. Although all of the above factors have various differentiation-inducing capabilities, specific cell types can be generated through more specific production methods.
[1114] For example, in cases requiring cardiac progenitor cells, cells can be co-incubated with a reprogramming composition comprising one or more GSK3 inhibitors / WNT agonists, TGF-β inhibitors, extracellular signal-regulated kinase 1 (ERK1) inhibitors, Ras GTPase activator (Ras-GAP) inhibitors, Oct-4 activators, p160ROCK inhibitors (where p160ROCK is a rho-associated protein kinase), iron chelators and / or KDM5B inhibitors, G9a histone methyltransferase inhibitors, multiple growth factor receptor (e.g., PDGF receptor β) inhibitors, protein kinase receptor inhibitors, PDGF-BB receptor inhibitors, and any combination thereof. The composition may contain at least two, three, four, five, six, seven, or eight reagents. After incubation in a reprogramming medium, the cells can subsequently be incubated in a first and / or second cardiac induction medium. The basal medium supplemented with the reprogramming reagent or inducer can be a convenient cell culture medium. Examples of usable cell culture media include mTESR-1® medium (StemCell Technologies, Inc., Vancouver, California), or Essential 8® medium (LifeTechnologies, Inc.) for use on Matrigel substrate (BDBiosciences, NJ) or Corning® Synthemax surfaces, or Johansson and Wiles CDM with added insulin, transferrin, lipids, and polyvinyl alcohol (PVA) to replace bovine serum albumin (BSA). Examples of commercially available media also include, but are not limited to, Duchenne Modified Eagle Medium (DMEM), Minimum Essential Medium (MEM), Basal Eagle Medium (BME), RPMI 1640, Ham's F-10, Ham's F-12, α-Minimum Essential Medium (aMEM), Glasgow's Minimum Essential Medium (G-MEM), Iscove's Modified Duchenne Medium, or universal media for pluripotent cells such as X-VIVO (Lonza) or hematopoietic basal medium.
[1115] The starting cells can be dispersed in a cell culture medium containing the reprogramming composition at a density sufficient to support cell expansion. For example, in the chosen cell culture medium, approximately 1 to 10 10 Individual cells can be contacted with the reprogramming composition, particularly when the cells are maintained at approximately 1 to approximately 10. 8 Cell density of cells per milliliter, approximately 100 to approximately 10 7 Cell density of cells per milliliter, or approximately 1000 to approximately 1000. 6 When the cell density is 1 cell / mL.
[1116] The time it takes for the initiating cells to transform into cardiac progenitor cells and cardiomyocytes may vary. For example, the initiating cells can be co-incubated with the reprogramming composition until the expression of cardiac or cardiomyocyte markers is observed. Such cardiac or cardiomyocyte markers may include any of the following: α-actin, MLC2v, MY20, cMHC, NKX2-5, MEF2c, GATA4, ISL1, cTNT, cTNI, MLC2a, and any combination thereof.
[1117] Incubation can be performed in any of the compositions described herein, for example, until the starting cells express early cardiac progenitor markers. Such early cardiac progenitor markers include GATA4, ISL1, or combinations thereof. Early cardiac progenitor markers (such as GATA4 and / or ISL1) may be expressed after cells have been incubated using the compositions and methods described herein for approximately 6, 8, 9, 10, 11, or 12 days.
[1118] Cells can be incubated until late cardiac progenitor cell markers (such as NKX2-5, MEF2c, or combinations thereof) are expressed. Late cardiac progenitor cell markers (such as NKX2-5 and / or MEF2c) may be expressed after approximately 14, 15, 16, 17, or 18 days of incubation using the compositions and methods described herein.
[1119] In some implementations, the starting cells may be co-incubated with reprogramming medium under cell culture conditions for about 1 to about 15 days, about 2 to about 12 days, about 3 to about 10 days, about 4 to about 8 days, about 5 to about 7 days, or about 6 days.
[1120] After incubation in reprogramming medium, the maturation of the cardiac phenotype can be induced by incubating the cells in a first cardiac induction medium (such as CIM1) for approximately 1 to approximately 20 days, approximately 2 to approximately 14 days, approximately 3 to approximately 8 days, approximately 4 to approximately 6 days, or approximately 5 days.
[1121] After incubation in the first heart-induction medium (such as CIM1), cells can be transferred to the second heart-induction medium (such as CIM2) and incubated for approximately 1 day to approximately 40 days, approximately 3 days to approximately 36 days, approximately 5 days to approximately 33 days, approximately 7 days to approximately 30 days, approximately 10 days to approximately 27 days, approximately 15 days to approximately 25 days, or approximately 20 days to approximately 22 days.
[1122] Cardiac cardiomyocytes exhibit several heart-specific electrophysiological properties. One electrophysiological feature is the action potential, a short-term event in which the potential difference between the inside and outside of each cardiac cell continuously rises and falls along a fixed trajectory. Another electrophysiological feature of cardiomyocytes is the presence of free calcium in the cytoplasm. 2+Periodic changes in concentration (called Ca) 2+ Transient changes (TDCs) are used to regulate the contraction and relaxation processes of cardiomyocytes. These TDCs can be detected and evaluated to determine whether a cell population has been reprogrammed into cardiomyocytes.
[1123] Therefore, such methods can be used to generate cardiac progenitor cells or cardiomyocyte populations that can be transplanted into subjects or used in experiments.
[1124] In some implementations, reprogrammed cell populations (in multiple reprogramming stages) can be frozen at liquid nitrogen temperatures for a period of time and then thawed for later use. If freezing is required, the reprogrammed cell populations can be stored in a mixture of 10% DMSO, 50% FCS, and 40% RPMI 1640 medium. Once thawed, the cells can be expanded by culturing them in a suitable medium, which may contain selected growth factors, vitamins, feeder cells, and other components chosen by those skilled in the art.
[1125] The reprogrammed cells described herein can be used for tissue reconstruction or regeneration in human patients or other subjects requiring such treatment. The cells must be administered in a manner that allows them to be transplanted or migrated to diseased or damaged tissue sites and to reconstruct or regenerate the functionally deficient areas. Several devices are available that can be adapted for administering the cells, for example, to cardiac tissue.
[1126] For treatment, reprogrammed cardiac progenitor cells, cardiomyocytes, and / or pharmaceutical compositions can be administered locally or systemically. Reprogrammed cell populations can be introduced via injection, catheter, implantable devices, etc. The reprogrammed cell population can be administered with any physiologically acceptable adjuvant or carrier that does not adversely affect the cells. For example, cardiac progenitor cells, cardiomyocytes, and / or pharmaceutical compositions can be administered intravenously or via intracardiac routes (e.g., epicardial or intramyocardial). Methods of administering the cardiac progenitor cells, cardiomyocytes, and / or pharmaceutical compositions of the present invention to subjects, particularly human subjects, include injecting or implanting these cells into a target site of the subject. The cells of the present invention can be placed in a delivery device that, after injection or implantation into the subject, facilitates cell delivery. Such delivery devices include tubular structures, such as catheters, for injecting cells and fluids into the subject. The tubular structure may also additionally include a needle (e.g., a syringe) through which the cells of the present invention can be introduced into the subject from the desired location. Kits described herein may include such devices.
[1127] Cardiac progenitor cells and cardiomyocytes can be placed in various forms within such delivery devices (e.g., syringes). Reprogrammed cell populations can be provided in the form of pharmaceutical compositions. Such compositions may include isotonic excipients prepared under adequate aseptic conditions and suitable for human administration. For general principles of pharmaceutical formulation, readers may refer to: *CELL THERAPY: STEM CELLTRANSPLANTATION*, *GENE THERAPY*, and *CELLULAR IMMUNOTIHERAPY*, by G. Morstyn & W. Sheridan eds, Cambridge University Press, 1996; and *HEMATOPOIETIC STEM CELLTHERAPY*, ED Ball, J. Lister & P. Law, Churchill Livingstone, 2000. The selection of any accompanying components of cell excipients and compositions including reprogrammed cell populations can be optimized according to the route of administration and / or device used.
[1128] As used herein, the term "solution" includes a carrier or diluent capable of maintaining the viability of the cardiomyocytes of the present invention. Carriers and diluents that can be used in conjunction with this aspect of the invention include saline, aqueous buffer solutions, physiologically acceptable solvents, and / or dispersion media. The use of such carriers and diluents is well known in the art. The solution is preferably sterile and liquid to allow for injection. For transplantation, a solution containing a suspension of cardiomyocytes can be aspirated into a syringe, and the cell-containing solution can be administered to an anesthetized transplant recipient. Multiple injections can be performed using this procedure.
[1129] The composition, cardiac progenitor cells, and / or cardiomyocytes may also be embedded in a supporting matrix. Compositions containing reprogrammed cell populations may also include or be supplemented with one or more other components that promote reprogrammed cell implantation or functional mobilization. Suitable components include matrix proteins that support or promote reprogrammed cell adhesion, or helper cell types such as cardiac pacemakers or cardiac cells at different stages of maturity. In another embodiment, the composition may include a physiologically acceptable matrix scaffold. This physiologically acceptable matrix scaffold may be reabsorbable and / or biodegradable.
[1130] The reprogrammed cell population generated by the methods described herein may contain a low percentage of non-cardiac cells (such as fibroblasts). For example, in a reprogrammed cell population used in a composition or administered to a subject, the proportion of non-cardiac cells in the total cells of the cell population may be less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 12%, less than about 10%, less than about 8%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1%.
[1131] Multiple cell types are capable of migrating to suitable sites within the subject's body for regeneration and differentiation. To determine the suitability of various therapeutic administration regimens and dosages of the cell composition, cells can first be tested in suitable animal models. At one level, the ability of cells to survive in vivo and maintain their phenotype needs to be assessed. Cells can also be evaluated to determine whether they migrate to diseased or damaged sites in vivo, or to determine appropriate dosages (such as appropriate cell numbers and / or frequency of cell administration). The cell composition can be administered to immunodeficient animals (such as nude mice, or animals immunodeficient through chemical methods or radiation treatment). Tissue can be harvested after a period of regrowth, and the administered cells or their progeny can be assessed to determine whether they still exist, survive, and / or have migrated to intended or unintended locations.
[1132] Injected cells can be tracked using various methods. For example, cells containing or expressing detectable markers (such as green fluorescent protein or β-galactosidase) can be easily detected. Cells can be pre-labeled, for example using BrdU or […]. 3 [H]-thymidine, or by introducing an expression cassette capable of expressing green fluorescent protein or β-galactosidase. Alternatively, these cells can be detected by cellular markers expressed by the reprogrammed cells, such as human-specific antigens, which are not expressed in the animals used for testing. The presence and phenotype of the applied reprogrammed cell population can be assessed by fluorescence microscopy (e.g., detection of green fluorescent protein or β-galactosidase), immunohistochemistry (e.g., using antibodies against human antigens), ELISA (using antibodies against human antigens), or RT-PCR analysis using primers and hybridization conditions that specifically amplify human polynucleotides.
[1133] Therefore, those skilled in the art can optimize the dosage and frequency of application.
[1134] Pharmaceutical Composition This invention also relates to reprogramming compositions containing one or more of the following chemical reagents: GSK3 inhibitors, WNT agonists, TGF-β inhibitors, extracellular signal-regulated kinase 1 (ERK1) inhibitors, Ras GTPase-activated protein (Ras-GAP) inhibitors, Oct-4 activators, p160ROCK inhibitors (wherein p160ROCK is a rho-associated protein kinase), iron chelators and / or KDM5B inhibitors, G9a histone methyltransferase inhibitors, multiple growth factor receptor (e.g., PDGF receptor β) inhibitors, protein kinase receptor inhibitors, PDGF-BB receptor inhibitors, and any combination thereof. For example, the composition may contain at least two reagents, or at least three reagents, or at least four reagents, or at least five reagents, or at least six reagents, or at least seven reagents, or at least eight reagents, or at least nine reagents. The composition may also contain reprogrammed cells.
[1135] For example, such reprogramming compositions (9C) may include CHIR99021, A83-01, SC1, OAC, Y27632, BIX-01294, AS8351, SU16f, and JNJ-10198409. As described herein, PBIT may be used instead of AS8351.
[1136] The present invention also relates to independent cardiac induction compositions comprising one or more of the following chemical agents: glycogen synthase kinase 3 (GSK3) inhibitors, and growth factors (such as bone morphogenetic proteins, TGF-β family members, vascular endothelial growth factor (VEGF), or any combination thereof).
[1137] The compositions of this invention can be pharmaceutical compositions. In some embodiments, the composition may include a pharmaceutically acceptable carrier. "Pharmaceutically acceptable" means that the carrier, diluent, excipient, and / or salt are compatible with other components of the formulation and are harmless to its receptors.
[1138] The composition may contain any of the reagents or compounds described herein in an amount sufficient to reprogram cells into a cardiac cell type. For example, the composition may contain any of the reagents or compounds described herein in an amount sufficient to induce cells to express cardiac or cardiomyocyte markers. Such cardiac or cardiomyocyte markers may include any of the following markers: α-actin, MLC2v, MY20, cMHC, NKX2-5, MEF2c, GATA4, ISL1, cTNT, cTNI, MLC2a, and any combination thereof. Incubation may be performed in any of the compositions described herein, for example, until the initiating cells express early cardiac progenitor cell markers. Such early cardiac progenitor cell markers include GATA4, ISL1, or combinations thereof. Early cardiac progenitor cell markers (such as GATA4 and / or ISL1) may be expressed after cells have been incubated using the compositions and methods described herein for approximately 6 days, approximately 8 days, approximately 9 days, approximately 10 days, approximately 11 days, or approximately 12 days.
[1139] In some embodiments, the therapeutic composition is applied in a "therapeuticly effective amount." This therapeutically effective amount is sufficient to achieve the desired physiological effect, such as treating a symptom, condition, or disease, or alleviating the symptoms of said symptom, condition, or disease. For example, a therapeutic agent may be applied to treat any of the symptom, condition, or disease described herein. Examples include congestive heart failure, myocardial infarction, myocardial ischemia, myocarditis, arrhythmia, or any combination thereof.
[1140] To achieve the desired effect, the composition can be prepared in a single dose or in multiple doses. For example, GSK3 inhibitors, WNT agonists, TGF-β inhibitors, extracellular signal-regulated kinase 1 (ERK1) inhibitors, Ras GTPase activator (Ras-GAP) inhibitors, Oct-4 activators, p160ROCK inhibitors (where p160ROCK is a rho-associated protein kinase), iron chelators and / or KDM5B inhibitors, G9a histone methyltransferase inhibitors, multiple growth factor receptors (such as PDGF receptor β) inhibitors, protein kinase receptor inhibitors, PDGF-BB receptor inhibitors and / or growth factors (such as any CIM1 growth factor) may be present in the composition at the levels described above, or at a level of at least about 0.01 mg / kg to about 500 to 750 mg / kg, at least about 0.01 mg / kg to about 300 to 500 mg / kg, at least about 0.1 mg / kg to about 100 to 300 mg / kg, or at least about 1 mg / kg to about 50 to 100 mg / kg, but other doses may also produce beneficial effects. Dosage varies depending on a number of factors, including but not limited to the combination of compounds used, the disease, the mammal's weight, physical condition, health status, age, and other physiological factors. Clinicians can easily determine these factors using animal models or other testing systems available in the field.
[1141] For example, the reprogramming composition may include CHIR99021 (e.g., about 10 to 20 μM), A83-01 (e.g., about 0.5 to 1.0 μM), SC1 (e.g., about 0.5 to 1.0 μM), OAC (e.g., about 1 to 10 μM), Y27632 (e.g., about 5 to 10 μM), BIX-01294 (e.g., about 0.5 to 2.0 μM), AS8351 (e.g., about 1.0 to 3.0 μM), SU16f (e.g., about 2 to 5 μM), and JNJ-10198409 (e.g., about 0.05 to 0.2 μM), as described herein, and PBIT (e.g., about 10 μM).
[1142] Depending on the disease or lesion to be treated, reprogrammed cells can be incorporated into the composition in varying amounts. For example, the composition can be prepared in a liquid form for topical or systemic application, containing approximately 10 3 To about 10 12 One reprogrammed cell, approximately 10 4 To about 10 10 One reprogrammed cell or about 10 5 To about 10 8 Reprogrammed cells. One or more of the following types of compounds may also be present in the composition with the cells: GSK3 inhibitors, WNT agonists, TGF-β inhibitors, extracellular signal-regulated kinase 1 (ERK1) inhibitors, Ras GTPase activator (Ras-GAP) inhibitors, Oct-4 activators, p160ROCK inhibitors (where p160ROCK is a rho-associated protein kinase), iron chelators and / or KDM5B inhibitors, G9a histone methyltransferase inhibitors, multiple growth factor receptors (such as PDGF receptor β) inhibitors, protein kinase receptor inhibitors, PDGF-BB receptor inhibitors and / or one or more growth factors (such as any CIM1 growth factor).
[1143] The composition can be administered in a single dose, multiple doses, continuously, or intermittently, depending on factors such as the recipient's physiological condition, whether the purpose of administration is to address traumatic injury or to achieve a more durable therapeutic effect, and other factors known to those skilled in the art. Similarly, cells can be contacted with the composition continuously or intermittently, depending on factors such as the need for reprogrammed cells, production schedule, operator convenience, and the physiological condition of the selected recipient. The application or contact of cells with the composition of the present invention can be substantially continuous over a predetermined period of time, or it can be administered in a series of interval doses. Both local and systemic administration to the recipient and / or subject are considered.
[1144] To prepare the composition, the corresponding compound must be synthesized and / or cells generated, and the components purified as needed or anticipated. The compound, cells, and / or other reagents may be suspended in a pharmaceutically acceptable carrier. If the composition contains only the compound and no cells, it may be lyophilized. The compound and cells may be adjusted to appropriate concentrations and optionally combined with other reagents. The absolute weight of a given compound and / or other reagent contained in a unit dose may vary significantly. For example, at least one compound may be administered in doses of about 0.01 to about 2 g, or about 0.1 to about 500 mg. Alternatively, the unit dose may vary from about 0.01 g to about 50 g, from about 0.01 g to about 35 g, from about 0.1 g to about 25 g, from about 0.5 g to about 12 g, from about 0.5 g to about 8 g, from about 0.5 g to about 4 g, or from about 0.5 g to about 2 g.
[1145] The daily dose of the compound may also vary. Such daily dose ranges may be, for example, about 0.1 g / day to about 50 g / day, about 0.1 g / day to about 25 g / day, about 0.1 g / day to about 12 g / day, about 0.5 g / day to about 8 g / day, about 0.5 g / day to about 4 g / day, and about 0.5 g / day to about 2 g / day.
[1146] It should be understood that the amount of compound and cells used for treatment depends not only on the specific type of carrier chosen, but also on the route of administration, the nature of the condition to be treated, and the patient's age and health status. Ultimately, caregivers can determine the appropriate dosage. The pharmaceutical composition can be formulated into a single-use unit dosage form in appropriate proportions of the compounds for administration alone or in combination with cells. Cells can be provided alone and used in combination with a liquid solution of the compound composition, or administered alone. The compounds can also be formulated as sustained-release formulations (e.g., using microencapsulation technology, see WO 94 / 07529 and U.S. Patent No. 4,962,091). Where appropriate, the formulation can be conveniently presented in a single-use unit dosage form and can be prepared by any method well known in the pharmaceutical industry. Such methods may include the step of mixing the therapeutic agent with a liquid carrier, a solid matrix, a semi-solid carrier, a finely dispersed solid carrier, or a combination thereof, and then, if desired, introducing or shaping the product into the desired delivery system. One or more suitable unit dosage forms containing compounds and / or reprogrammed cells can be administered via a variety of routes, including parenteral (including subcutaneous, intravenous, intramuscular, and intraperitoneal), intracranial, intraspinal, oral, rectal, skin, transdermal, intrathoracic, intrapulmonary, and intranasal (respiratory) routes.
[1147] In one embodiment, iPSCs are generated from multiple sources and used to generate insulin-secreting cells in vitro. In other embodiments, the process is performed in vivo. Methods for generating iPSCs from somatic cells involve the forced expression of a set of polypeptides or inducible factors (IFs). IFs known in the art include, but are not limited to, polypeptides encoded by the following genes: c-Myc, Oct3 / 4, Sox2, and Klf4. Additionally, small molecule compounds such as histone deacetylation inhibitors can be used, or IFs can be conjugated with small molecules to generate iPSCs. Somatic cells can be used directly in the reference induction method, i.e., without culture or passage; or, somatic cells can be cultured and / or passaged prior to use in the reference induction method. The induced cells can be induced from somatic cells of a newly generated donor or a non-pluripotent donor, as described in U.S. Patent Application No. 12 / 157,967 (filed June 13, 2008; first inventor: Kazuhiro Sakurada), which is incorporated herein by reference in its entirety. The induced stem cells can be derived from any cell type, including but not limited to the types described herein.
[1148] IPSCs or iSCs can be used directly for differentiation or regenerative medicine. In other cases, iPSCs or iSCs may be stored by regenerative medicine companies, stem cell technology companies, or third-party institutions. Alternatively, iPSCs or iSCs may be expanded before or after storage using the culture methods described in U.S. Patent Application No. 12 / 157,967 (filed June 13, 2008; first inventor: Kazuhiro Sakurada), which is incorporated herein by reference in its entirety. iSCs may be stored in any manner that preserves their pluripotency or multipotent potential, including cryopreservation and culture. In some cases, donors, potential recipients of iPSCs or their derivatives, or payees may be required to pay for the preparation and / or delivery of iPSCs or differentiated cells or tissues. In some cases, kits containing iPSC-generating agents may be available for sale. During induction, certain peptides are forcibly expressed in cultured cells for a period of time, followed by screening of induced cells to characterize a range of morphological and gene expression properties of pluripotent and multipotent stem cells. Induced cells that meet these screening criteria may be further subcloned and expanded. In some cases, the cells to be induced may be pre-cultured for a period of time before the induction procedure. Alternatively, the cells to be induced may be used directly for the induction process without a prior culture period. In some embodiments, the type of cell culture medium used is the same or highly similar before, during, and after the induction process. In other cases, different cell culture media are used at different time points. For example, one type of medium may be used directly before the induction process, while a second type of medium is used during the induction process. A third type of medium may sometimes be used during the induction process. Cells may be cultured in a medium for which a specific serum has been added. In some embodiments, the serum is fetal bovine serum (FBS). The serum may also be fetal calf serum (FCS). In some cases, the serum may be human AB serum. Serum mixtures may also be used, such as FBS and human AB, FBS and FCS, or a mixture of FCS and human AB. Cell culture may be performed under low serum conditions before, during, or after induction. "Low serum culture conditions" refers to cell culture media containing serum at concentrations ranging from 0% (v / v) (i.e., serum-free) to approximately 5% (v / v), such as 0% to 2%, 0% to 2.5%, 0% to 3%, 0% to 4%, 0% to 5%, 0.1% to 2%, 0.1% to 5%, 0.1%, 0.5%, 1%, 1.2%, 1.5%, 2%, 2.5%, 3%, 3.5%, or 4%. In some embodiments, the serum concentration is from about 0% to about 2%. In some cases, the serum concentration is about 2%. In some cases, the serum concentration is preferably 2% or lower. In other embodiments, cells are cultured under "high serum conditions," i.e., above 5% serum to about 20% serum, such as 6%, 7%, 8%, 10%, 12%, 15%, or 20%.Culture under high serum conditions may occur before, during, and / or after induction. Some representative culture media that can be used to culture cells include: MAPC, FBM, ES, MEF-conditioned ES (MC-ES), and mTeSR™ (available, for example, from StemCell Technologies, Vancouver, Canada), see: Ludwig et al (2006), Nat Biotechnol, 24(2):185-187. In other cases, as described in Skottman et al (2006), Reproduction, 132(5):691-698, alternative culture conditions for human ES cell growth are used. In some embodiments, cells are cultured in MAPC, FBM, MC-ES, or mTeSR™ before and / or during the introduction of the inducing factor; and in MC-ES or mTeSR™ medium later in the induction process. MAPC (2% FBS) medium may include: 60% Duchenne modified Eagle medium (low glucose), 40% MCDB 201, insulin-transferrin-selenium supplement (0.01 mg / ml insulin; 0.0055 mg / ml transferrin; 0.005 μg / ml sodium selenite), 1×linolenic acid albumin (1 mg / mL albumin; 2 moles of linolenic acid / moles of albumin), 1 nM dexamethasone, 2% fetal bovine serum, 1 nM dexamethasone, 10⁻⁴ M ascorbic acid, and 10 pg / ml gentamicin. FBM (2% FBS) medium may include: MCDB202 modified medium, 2% fetal bovine serum, 5 μg / ml insulin, 50 mg / ml gentamicin, and 50 ng / ml amphotericin B. ES medium may include: 40% Duchenne Modified Eagle Medium (DMEM), 40% F12 medium, 2 mM L-glutamine, 1× non-essential amino acids (Sigma, Inc., St. Louis, Missouri), 20% KnockOut™ serum substitute (Invitrogen, Inc., Carlsbad, California), and 10 μg / ml gentamicin. MC-ES medium can be prepared as follows: Condition ES medium is prepared using mitomycin C-treated mouse pluripotent fibroblasts (MEFs), collected, filtered through a 0.45 μM filter, and supplemented with approximately 0.1 mM β-mercaptoethanol, approximately 10 ng / ml bFGF or FGF-2, and optionally approximately 10 ng / ml activin A. In some cases, irradiated MEFs are used instead of mitomycin C-treated MEFs.When culturing cells under low or high serum conditions, the culture medium may include one or more growth factors, such as fibroblast growth factor (FGF)-2; basic FGF (bFGF); platelet-derived growth factor (PDGF), epidermal growth factor (EGF); insulin-like growth factor (IGF); or insulin. Other growth factors that may be used to supplement cell culture medium include, but are not limited to, one or more of the following: transforming growth factor-1 (TGF-1), activin A, noggin, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophic factor (NT)-1, NT-2, or NT-3. In some cases, one or more of these factors may be used to replace bFGF or FGF-2 in MC-ES medium or other cell culture media. In some cases, the concentration of growth factors in the culture medium (e.g., MAPC, FBM, MC-ES, mTeSR™) is from about 2 ng / ml to about 20 ng / ml, for example, about 2 ng / ml, 3 ng / ml, 4 ng / ml, 5 ng / ml, 6 ng / ml, 7 ng / ml, 8 ng / ml, 10 ng / ml, 12 ng / ml, 14 ng / ml, 15 ng / ml, 17 ng / ml, or 20 ng / ml. In some embodiments, the concentration of bFGF or FGF-2 is from about 2 ng / ml to about 5 ng / ml; from about 5 ng / ml to about 8 ng / ml; from about 9 ng / ml to about 11 ng / ml; from about 11 ng / ml to about 15 ng / ml; or from about 15 ng / ml to about 20 ng / ml. Growth factors can be used alone or in combination. For example, FGF-2 can be added to the culture medium alone; in another instance, both PDGF and EGF can be added. In some instances, once forced expression of a gene or peptide in the cell is initiated (e.g., immediately following a retroviral infection), the “induced cells” will be maintained in the MC-ES medium described herein.
[1149] In some embodiments, cells are maintained in the presence of rho or a rho-associated protein kinase (ROCK) inhibitor to reduce apoptosis. In some cases, an inhibitor of Rho-associated kinase is added to the culture medium. For example, the addition of a Rho-associated kinase (Rho-associated coiled-coil protein kinase) inhibitor, such as Y-27632 (Calbiochem; water-soluble) or fasudil (HA1077: Calbiochem), can be used to culture the human pluripotent and multipotent stem cells of the present invention. In some cases, the concentration of Y-27632 or fasudil is from about 5 μM to about 20 μM, for example, about 5 μM, 10 μM, 15 μM, or 20 μM. Cells may be cultured for about 1 to about 12 days, for example, 2 days, 3 days, 4.5 days, 5 days, 6.5 days, 7 days, 8 days, 9 days, 10 days, or any other number of days between about 1 day and about 12 days, prior to the induction methods described herein. In some cases, induced cells are cultured in complete ES medium at 37°C and 5% CO2 in an incubator, with the medium changed approximately every 1 to 2 days. In some embodiments, induced cells are cultured and observed for approximately 14 to approximately 40 days, for example, 15, 16, 17, 18, 19, 20, 23, 24, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38 days, or any other time period between approximately 14 and approximately 40 days, before identification and selection of clones including “induced cells” based on morphological characteristics. Morphological characteristics used to identify induced cell clones include, but are not limited to: small cell size and high nucleocytoplasmic ratio; formation of small monolayer colonies within the gaps between parental cells (e.g., between fibroblasts). Cells can be cultured at approximately 1 × 10⁻⁶ cells per cell line. 3 cells / cm 2 To approximately 1×10 4 cells / cm 2 Seed at a cell density of, for example, 2 × 10⁶ cells. 3 cells / cm 2 3.5×10 3 cells / cm 2 6×10 3 cells / cm 2 7×10 3 cells / cm 2 9×10 3 cells / cm 2 or about 1×10 3 cells / cm 2 To approximately 1×10 4 cells / cm 2Any other cell density. Cells can be directly seeded and cultured on tissue culture-grade plastic surfaces. Alternatively, cells can be seeded and cultured on coated substrates, such as those coated with fibronectin, gelatin, Matrigel™, collagen, or laminin. Suitable cell culture containers include, for example, 35 mm, 60 mm, 100 mm, and 150 mm cell culture dishes, 6-well cell culture plates, and other equivalent cell culture containers. In some cases, cells are cultured using feeder cells. For example, cells can be cultured on a layer or blanket formed from MEF.
[1150] Low serum concentration culture media may be particularly useful for enriching undifferentiated stem cells. Undifferentiated cells cultured under low serum conditions may share or not share certain characteristics with MSCs, MAPCs, and / or MIAMI cells. Phenotypic differences may stem in part from the culture methods used to obtain MSCs, MAPCs, and / or MIAMI cells. For example, when culturing tissues (such as bone marrow, fat, muscle, or skin) in media containing high concentrations of serum (5% or higher), MSCs are typically obtained by isolating non-hematopoietic cells (such as mesenchymal cells) adhering to plastic culture dishes. However, even under these culture conditions, very small numbers of undifferentiated cells can be retained, especially when cells are passaged under certain culture conditions (e.g., low passage counts or low-density culture). In some embodiments, for culturing and expanding human pluripotent stem cells induced from the undifferentiated stem cells of the present invention present in postnatal human tissues, it is preferable to passage the cells every 5 to 7 days in a medium containing the additives described herein on MEF-covered plastic culture dishes or matrigel-coated plastic culture dishes. In some cases, cells can be cultured at low densities, which can be achieved by passaged at a ratio of approximately 1:6 to 1:3, or at a density of 10... 3 cells / cm 2 Up to 3×10 4 cells / cm 2 This is achieved by seeding cells at a high density. Primary culture typically occurs immediately after cells are isolated from a donor (e.g., human). Primary cells can be passaged a second, third, fourth, or more than four times. A "second" passage refers to primary cells being passaged once, a "third" passage refers to primary cells being passaged twice, a "fourth" passage refers to primary cells being passaged three times, and so on. The culture techniques described herein typically cover the culture process from primary culture to the fourth passage, but other culture stages may also be used. Preferably, cells are cultured from primary culture to the second passage.
[1151] Various methods can be used to induce cells to possess pluripotency or multiple potentiality. In some embodiments, methods for inducing pluripotency or multiple potentiality in one or more cells include the forced expression of a set of inducible factors (IFs). In some cases, this set of IFs includes one or more of the following: Oct3 / 4 peptide, Sox2 peptide, Klf4 peptide, or c-Myc peptide. In some cases, the set does not include c-Myc peptides. For example, the set of IFs may include Oct3 / 4 peptide, Sox2 peptide, and Klf4 peptide, but not c-Myc peptides. In some cases, the set of IFs does not include peptides that may increase the risk of cell transformation. In some cases, the set may include c-Myc peptides. In some cases, c-Myc peptides are constitutively active variants of c-Myc. In some cases, the set includes c-Myc peptides capable of inducing activity, such as c-Myc-ER peptides.
[1152] In other cases, this group of IFs may include: Oct3 / 4 peptide, Sox2 peptide, and Klf4 peptide, but excludes TERT peptide, SV40 large T antigen peptide, HPV16 E6 peptide, HPV16 E7 peptide, or Bmil peptide. In some cases, this group of IFs does not include TERT peptide. In some cases, this group of IFs does not include SV40 large T antigen. In other cases, this group of IFs does not include HPV16 E6 peptide or HPV16 E7 peptide.
[1153] In some cases, this group of IFs includes three IFs, two of which are Oct3 / 4 peptides and Sox2 peptides. In other cases, this group of IFs includes two IFs, where the two peptides are c-Myc peptides and Sox2 peptides. In some cases, this group of inducing factors is limited to Oct3 / 4, Sox2, and Klf4 peptides. In other cases, this group of inducing factors may be limited to four IFs: Oct3 / 4 peptide, Sox2 peptide, Klf4 peptide, and c-Myc peptide. IF groups may include IFs other than Oct3 / 4, Sox2, and Klf4 peptides. Such additional IFs include, but are not limited to: Nanog, TERT, LIN28, CYP26A1, GDF3, FoxD3, Zfp42, Dnmt3b, Ecat1, and Tcl1 peptides. In some cases, this group of additional IFs does not include c-Myc peptides. In some cases, this group of additional IFs does not include peptides that may increase the risk of cell transformation. Forced expression of IF can be maintained for a period of at least approximately 7 days to at least approximately 40 days, for example, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 25, 30, 33, or 37 days. First, a cell population (starting cell population) is provided, which includes at least one differentiateable cell. In some embodiments, the differentiateable cells are pancreatic progenitor cells expressing PDX1 and NKX6.1.
[1154] In some embodiments, the starting cell population includes at least 5% pancreatic progenitor cells, such as at least 10% pancreatic progenitor cells, such as at least 15% pancreatic progenitor cells, such as at least 20% pancreatic progenitor cells, such as at least 25% pancreatic progenitor cells, such as at least 30% pancreatic progenitor cells, such as at least 35% pancreatic progenitor cells, such as at least 40% pancreatic progenitor cells, such as at least 45% pancreatic progenitor cells, such as at least 50% pancreatic progenitor cells, such as at least 55% pancreatic progenitor cells, such as at least 60% pancreatic progenitor cells, such as at least 65% pancreatic progenitor cells, such as at least 70% pancreatic progenitor cells, such as at least 75% pancreatic progenitor cells, such as at least 80% pancreatic progenitor cells, such as at least 85% pancreatic progenitor cells, such as at least 90% pancreatic progenitor cells, such as at least 95% pancreatic progenitor cells. To determine the proportion of progenitor cells in a cell population (e.g., the initial population), methods known in the art can be used, such as, but not limited to, immunostaining or flow cytometry.
[1155] Without being bound by theory, the percentage of pancreatic progenitor cells in the starting cell population can be estimated by the expression of GP2. Therefore, in some embodiments, the starting cell population includes at least 5% of cells expressing GP2, such as at least 10% of cells expressing GP2, such as at least 15% of cells expressing GP2, such as at least 20% of cells expressing GP2, such as at least 25% of cells expressing GP2, such as at least 30% of cells expressing GP2, such as at least 35% of cells expressing GP2, such as at least 40% of cells expressing GP2, such as at least 45% of cells expressing GP2, such as at least 50% of cells expressing GP2, such as at least 55% of cells expressing GP2, such as at least 60% of cells expressing GP2, such as at least 65% of cells expressing GP2, such as at least 70% of cells expressing GP2, such as at least 75% of cells expressing GP2, such as at least 80% of cells expressing GP2, such as at least 85% of cells expressing GP2, such as at least 90% of pancreatic progenitor cells, and such as at least 95% of pancreatic progenitor cells. GP2 expression can be determined using methods known in the art, such as immunostaining, flow cytometry, or quantitative measurement of transcriptional levels. Similarly, without being bound by theory, the percentage of PDX1+NKX6.1+ cells in the starting cell population can be estimated by GP2 expression. Therefore, in some embodiments, the starting cell population includes at least 5% cells expressing GP2, such as at least 10% cells expressing GP2, such as at least 15% cells expressing GP2, such as at least 20% cells expressing GP2, such as at least 25% cells expressing GP2, such as at least 30% cells expressing GP2, such as at least 35% cells expressing GP2, such as at least 40% cells expressing GP2, such as at least 45% cells expressing GP2, such as at least 50% cells expressing GP2, such as at least 55% cells expressing GP2, such as at least 60% cells expressing GP2, such as at least 65% cells expressing GP2, such as at least 70% cells expressing GP2, such as at least 75% cells expressing GP2, such as at least 80% cells expressing GP2, such as at least 85% cells expressing GP2, such as at least 90% pancreatic progenitor cells, such as at least 95% pancreatic progenitor cells. GP2 expression can be determined by methods known in the art, such as immunostaining, flow cytometry, or quantitative measurement of transcriptional levels.
[1156] In some embodiments, the cell population may be derived from or isolated from an individual, such as, but not limited to, mammals (e.g., humans). In some embodiments, the differentiateable cells are pluripotent stem cells, such as human pluripotent stem cells (hPSCs). hPSCs include human induced pluripotent stem cells (hiPSCs and naïve human stem cells (NhSCs)). In one embodiment, the starting cell population is obtained from the pancreas, including fetal pancreas or adult pancreas. In one aspect, the pancreas is derived from a mammal, such as a human. In another embodiment, the starting cell population is a somatic cell population. In some embodiments, the starting cell population includes at least one pancreatic progenitor cell expressing PDX1 and NKX6.1, and the cell population is obtained autologously. In another aspect of the invention, the somatic cell population has been induced to dedifferentiate into pluripotent-like stem cells (e.g., ESCs, a type of pluripotent stem cell; for human ESCs, this is referred to as hESCs). Such dedifferentiated cells are also referred to as induced pluripotent stem cells (IPSCs; for human IPSCs, this is referred to as hIPSCs). In another embodiment, the starting cell population is ESCs or hESCs. In one embodiment, the starting cell population is obtained from ESCs or hESCs. In some embodiments, the starting cell population is a pluripotent stem cell population, such as ESC-like cells. In some embodiments, prior to performing steps viii) and ix) described herein, a cell population comprising at least one pancreatic progenitor cell can be obtained by methods known in the art. For example, differentiation can be induced in embryoid bodies and / or monolayer cell cultures or combinations thereof. In one aspect of the invention, the starting cell population is derived from mammals. In one aspect of the invention, the starting cell population is derived from humans.
[1157] Example 1: Generation of cardiac progenitor cells (α-myosin heavy chain) from induced pluripotent stem cells Fibroblast-derived induced pluripotent stem cells (iPSCs) were purchased from ATCC and cultured according to the manufacturer's instructions. Cells were seeded in commercially available cardiac differentiation medium (Stem Cell Technologies Inc., Vancouver, Canada) or in conditioned medium prepared from decellularized heart tissue seeded with mesenchymal stem cells in the presence of 100 pg / ml valproic acid. Cells were cultured for the time periods shown below. α-myosin heavy chain expression was determined by Western blotting and is expressed as a percentage of the control group. Results are shown in... Figure 1 middle.
[1158] Example 2: Generation of cardiac progenitor cells from induced pluripotent stem cells (c-kit) Fibroblast-derived induced pluripotent stem cells were purchased from ATCC and cultured according to the manufacturer's instructions. Cells were seeded either in commercially available cardiac differentiation medium (Stem Cell Technologies Inc., Vancouver, Canada) or in conditioned medium prepared from decellularized heart tissue seeded with mesenchymal stem cells. Troponin expression on cells was determined by Western blotting and expressed as a percentage of the control group. Results are shown in... Figure 2 middle.
[1159] Example 3: Generation of heart-forming progenitor cells (CD133) from induced pluripotent stem cells Fibroblast-derived induced pluripotent stem cells were purchased from ATCC and cultured according to the manufacturer's instructions. Cells were seeded in commercially available cardiac differentiation medium (Stem Cell Technologies Inc., Vancouver, Canada) or in conditioned medium prepared from decellularized heart tissue seeded with mesenchymal stem cells. Troponin expression on cells was determined by Western blotting and expressed as a percentage of the control group. Results are shown in... Figure 3 middle.
Claims
1. A method for generating tissue-specific progenitor cells from pluripotent stem cells, comprising exposing the pluripotent stem cells to factors generated by representative tissue cells.
2. The method of claim 1, wherein the pluripotent stem cells are capable of forming teratomas in immunodeficient mice.
3. The method of claim 1, wherein the pluripotent stem cells are generated by inducing pluripotency.
4. The method of claim 3, wherein the pluripotency is induced by applying a pluripotency factor together with one or more dedifferentiation factors.
5. The method of claim 4, wherein the dedifferentiation factor is a conditioned medium derived from embryonic stem cells.
6. The method of claim 5, wherein the dedifferentiation factor is a conditioned medium derived from pluripotent stem cells exposed to cellular stress.
7. The method of claim 6, wherein the cellular stress is selected from the following stressors: a) hypoxia; b) metabolic stress; c) high temperature; d) low temperature; e) hypotonic stress; f) hypertonic stress; and g) proteasome blockade stress.
8. The method of claim 1, wherein the factor produced by the representative tissue cells is a factor derived from decellularized tissue.
9. The method of claim 8, wherein the decellularized tissue is applied to a culture medium containing pluripotent stem cells.
10. A method for generating cardiac progenitor cells, comprising culturing pluripotent stem cells in a culture medium containing decellularized cardiac tissue.
11. The method of claim 10, wherein the pluripotent stem cell is an induced pluripotent stem cell.
12. The method of claim 10, wherein the culture medium contains valproic acid.
13. The method of claim 12, wherein the valproic acid is added to the culture medium at a concentration of 10 pg / ml to 100 ng / ml.
14. The method of claim 13, wherein the valproic acid is added to the culture medium at a concentration of 100 pg / ml to 10 ng / ml.
15. A method for generating cardiac progenitor cells, comprising co-culturing pluripotent stem cells with cardiac differentiation medium and mesenchymal stem cell conditioned medium.
16. The method of claim 15, wherein the centripetal differentiation medium is mixed with a stem cell conditioned medium produced by culturing stem cells on decellularized bone matrix.
17. The method of claim 16, wherein the stem cell conditioned medium is prepared by culturing bone marrow-derived mesenchymal stem cells on a decellularized bone matrix.
18. The method of claim 15, wherein the heart-forming differentiation medium contains valproic acid.
19. The method of claim 15, wherein the valproic acid is added to the culture medium at a concentration of 10 pg / ml to 100 ng / ml.
20. The method of claim 15, wherein the valproic acid is added to the culture medium at a concentration of 100 pg / ml to 10 ng / ml.
